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ABSTRACT
MRSA is a significant pathogen, which can cause a range of minor and
major infections both in the hospital and community environments. MRSA is
developing resistance to many antibiotics, including vancomycin, which is
now the first choice antibiotic to treat MRSA infections in the UK. This
together with the dearth of new antibiotics being introduced could see the
emergence of untreatable S. aureus strains. This has led to renewed
interest in alternative antimicrobial agents.
Lysostaphin is an endopeptidase produced by Staphylococcus simulans
biovar staphylolyticus, which cleaves the peptidoglycan cross-bridges of
other staphylococcal species. Lysostaphin has been investigated as a
potential therapeutic agent and has shown promise in in vitro and in vivo
studies and in clinical trials. However, resistance to lysostaphin is likely to
emerge and there will be a demand for second generation Iysostaphins
and/or other similar novel antimicrobials that can counteract this resistance.
This study describes the cloning, purification and assaying of an endolysin
of the S. aureus P68 bacteriophage. Lys16 lysin has previously been shown
to possess staphylolytic activity. This study demonstrates that the purified
recombinant protein is poorly soluble and is inactive against live cells.
The Atl autolysin of S. aureus was also investigated as a potential
antimicrobial. This study confirmed the hydrolytic profiles of the enzymes,
and a chimeric peptide incorporating the lysostaphin targeting domain with
the Atl glucosaminidase was designed. This did not confer greater activity
against S. aureus, although the targeting domains of each enzyme were
shown to utilise different cell surface receptors.
Finally, this study reports the development of a novel assay to measure the
activity of antimicrobial peptides against S. aureus, using a bioluminescence
reporter. This was shown to be a sensitive assay, able to distinguish small
differences in the activity of antimicrobial peptides.
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1. INTRODUCTION
1.1 THE THREAT OF MRSA
Staphylococcus aureus is a bacterium commonly found as a commensal
organism living on the human skin and mucosa. It is found in up to 30% of
the population living harmlessly on the skin, predominantly in the anterior
nares (Livermore, 2000). However, it is a versatile organism and if it is able
to gain access to the body it is able to colonise many other sites, often
causing disease (Lowy, 1998). S. aureus is the most common cause of skin
infections, entering either through a breach in the skin or as a result of blood
borne spread. It can be responsible for conditions ranging from boils
focussed around hair follicles, to scalded skin syndrome, which is caused by
strains of S. aureus producing the exfoliatin toxin (Iwatsuki et al., 2006).
S. aureus can also colonise bones and joints, being the most common
cause of osteomyelitis which can lead to permanent bone deformities, and
of suppurative arthritis (Davis, 2005). In the respiratory tract S. aureus can
cause pneumonia, where it is of particular concern for cystic fibrosis patients
(Burns et al., 1998). S. aureus is also a major cause of infective
endocarditis. If a heart valve's endothelial lining becomes damaged,
S. aureus is able to adhere to its surface, forming a vegetation. This is a
serious condition which can lead to congestive heart failure. Even with
aggressive antimicrobial therapy, the mortality rate of infective endocarditis
remains at up to 40% (Bashore, Cabell & Fowler, 2006).
S. aureus is also the most common cause of surgical wound infections. The
source of infection can be the patient's own microflora, a member of staff, or
equipment within the hospital environment (Anon, 2007). Such hospital
acquired infections may remain localised at the site of the surgical
procedure, but S. aureus may also invade the bloodstream and disseminate,
causing infections at other sites, such as those listed above. These
infections are often difficult to treat due to the problems of administering
suitable doses of the necessary antibiotics, to often deep seated infections.
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The predicament of hospital acquired S. aureus infections is worsened by
the ability of the organism to rapidly develop resistance to the antibiotics
used against it. Antibiotics have been used in the treatment of S. aureus
infections since the clinical introduction of penicillin in 1944. However,
penicillin resistant strains were isolated only two years later (Barber &
Rozwadowska-Dowenzko, 1948). Similarly, the introduction of methicillin, a
semi-synthetic penicillin; in 1959 was shortly followed by the emergence of
methicillin resistant S. aureus (MRSA) (Jevons, Coe &Parker, 1963).
MRSA has become a cause of great public concern and has received
considerable media attention, due to the prospect of untreatable strains
evolving and becoming entrenched within our hospitals. As a result,
mandatory MRSA bacteraemia surveillance has been introduced to acute
NHS Trusts in England. Currently, approximately forty percent of hospital
acquired staphylococcal bacteraemias are now identified as MRSA. From
October 2005 to March 2006 3,517 MRSA bacteraemia episodes were
reported in England (Anon, 2006). Since mandatory surveillance was
introduced the increase in MRSA incidence has been arrested, and thee has
been a slight reduction in the incidence rate. However, this remains a
dramatic increase from a rate of two percent in 1990 and poses a significant
threat to public health (Reacher et al., 2000). Between 2001 and 2005, the
number of death certificates mentioning S. aureus rose from 1,211 to 2,083,
with the percentage being specified as MRSA also increasing from 61 % to
78% (Anon, 2007b).
It is difficult to determine precise figures of deaths due to MRSA, as patients
who die with MRSA infections often have complex medical histories. A small
scale national study has shown that in half the cases where MRSA is
mentioned on the death certificate, it is probably not the main cause of
death. Furthermore, MRSA was not mentioned on the death certificates of
nearly half of the cases studied of patients with MRSA bacteraemia who
subsequently died, where MRSA was considered to have caused or
contributed to death (Anon, 2007c). There remains no doubt though, that
MRSA is a considerable cause of morbidity in UK hospitals.
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Resistance to methicillin is conferred by the mecA gene. This encodes an
altered penicillin binding protein (PBP 2') with a low affinity for ~ - I a c t a m s s
therefore allowing cross-linking of peptidoglycan to progress unaffected by
their presence (Brown & Reynolds, 1980; Hartman & Tomasz, 1984). The
mecA gene is carried on a mobile genetic element, the Staphylococcal
chromosomal cassette (SCC) mec (Katayama, Ito & Hiramatsu, 2000).
There are six main groups of SCCmec which insert into the S. aureus
chromosome (Enright, 2003; Ito et al., 2004; Oliveira, Milheirico & de
Lencastre, 2006). These mobile cassettes are believed to have been
transferred to S. aureus by a horizontal gene transfer event from another
staphylococcal species, possibly S. sciurii (Enright, 2003; Wu et al., 1996).
Various strains of MRSA have been isolated, showing a range of antibiotic
resistance profiles, many being multiple-drug resistant. The two most
common strains in the UK have been designated epidemic MRSA (EMRSA)
15 and 16.
A recent development In the evolution of MRSA is the emergence of
community acquired MRSA (cMRSA). Initial reports of community acquired
MRSA were from the USA, and cases have since been reported elsewhere,
including the UK (Baba et al., 2002). Community acquired MRSA is
associated with the Panton Valentine Leukocidin toxin and can cause
rapidly progressing fatal infections such as necrotizing fasciitis (Boyle-Vavra
& Daum, 2007; Miller et al., 2005) and necrotizing pneumonia (Francis et al.,
2005). Fit, healthy young adults appear to be equally susceptible to cMRSA
as the very old, or young, or infirm that are susceptible to hospital acquired
MRSA (Fridkin et al., 2005).
1.2 THE FAILURE OF CURRENT ANTIBIOTICS
Vancomycin is the antibiotic used most commonly in the treatment of MRSA
infections, and is often the drug of last resort. However, resistance of
S. aureus to vancomycin is also emerging. Vancomycin-intermediately-
susceptible S. aureus (VISA) has a lowered susceptibility due to alterations
in the peptidoglycan structure. The mechanisms for reduced susceptibility
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are varied in different isolates and include thickened cell walls and altered
peptidoglycan cross-linking. They confer the ability to sequester the drug
and reduce the amount of it able to reach its target site (Cui et al., 2000;
Sieradzki &Tomasz, 2003).
Vancomycin resistant S. aureus (VRSA) have also been isolated (Chang et
a/., 2003; Tenover et al., 2004). The vanA gene responsible for resistance is
believed to have been acquired by VRSA on a transposon from vancomycin
resistant enterococci (VRE).
Linezolid was clinically introduced In 2001. This represented the first
antibiotic from the oxazolidinones, the first new class of antibiotics for thirty
years (Zurenko et al., 2001). Linezolid resistant MRSA was isolated from a
patient within one year of its clinical introduction (Tsiodras et al., 2001 ).
The above examples highlight a pattern of resistance emerging amongst
S. aureus within two years of the clinical introduction of a new antibiotic.
This makes the development of novel conventional antibiotics an
unattractive prospect to pharmaceutical companies. Any new antibiotics that
are successfully introduced face the risk of becoming redundant before the
high costs of bringing the drug to market have been recouped. As a result
there is a lack of antibiotics in the drug development pipeline, at a time when
MRSA and other infections demand new treatment options to be available.
1.3 AS. AUREUS VACCINE
Vaccines are routinely used in the prevention of infection of several bacterial
infections. These include vaccinations against diseases caused by
Mycobacterium tuberculosis, Clostridium tetani and some Neisseria
meningitidis strains. The development of a vaccine against S. aureus holds
particular challenges. S. aureus is a versatile pathogen, exploiting many
environments within the human host. An ideal vaccine would need to
provide safe long term protection against the organism and its toxins
through comprehensive cell mediated and antibody responses. Currently
4
there are vaccines derived from the surface proteins of S. aureus under
development which have shown some promise in animal studies (Kuklin et
a/., 2006; Stranger-Jones, Bae & Schneewind, 2006). However, S. aureus
has demonstrated an unparalleled ability to mutate and evade the actions of
antibiotics. This adaptable organism may prove equally successful In
altering its cell surface proteins included in a subunit vaccine. A
polysaccharide conjugate vaccine, StaphVAX, recently failed a phase III
clinical trial, with a group of haemodialysis patients showing no reduction in
the incidence of S. aureus infections (Fattom et a/., 2004; Anon, 2005).
Along with concerns over the quality of the vaccine preparation this failure
was partly attributed to the emergence of S. aureus with increased virulence
(Anon, 2006b). Future vaccines may be at risk of failing in a similar fashion
as S. aureus continues to evolve.
Until a reliable vaccine is developed which S. aureus cannot evade there is
a requirement for novel treatments to be developed. In the event of a
successful S. aureus vaccine being introduced there will still remain
unprotected individuals who will develop infections, especially in countries
which cannot afford expensive protection campaigns. S. aureus will never
be eradicated as it exists as a commensal organism of humans and
animals. There will thus be a continuing demand on novel treatments for
S. aureus infections.
1.4 RENEWED INTEREST IN NOVEL ANTIMICROBIALS
Prior to the discovery of antibiotics and their clinical introduction there was
widespread interest in alternative antimicrobial therapies. These included
bacteriophage therapy and antimicrobial peptides. Research into these
alternatives waned as antibiotics proved to be successful in treating most
bacterial infections (Nathan, 2004). However, now that conventional
antibiotics are failing in the treatment of multiple-drug resistant MRSA and
other organisms, there is renewed interested in developing alternative
antimicrobials. There are currently enzybiotics against S. aureus under
5

against MRSA. The structure of staphylococcal peptidoglycan, and potential
cleavage sites are shown in Figure 1.1 (Schleifer & Kandler, 1972;
Loessner, 2005).
1.4.2 Bacteriophage endolysins
Bacteriophages are viruses that infect bacterial cells and were first
described by Frederick Twort in 1915 (Twort, 1915). The name, literally
"bacteria eaters", was coined by Felix d'Herelle who used bacteriophages in
the treatment of patients with bacterial dysentery (d'Herelle, 1917).
Bacteriophages were SUbsequently used in the treatment of several
bacterial infections. However, results were variable, often due to
inappropriate phages being used to treat an infection. Additionally the
complex pharmacokinetics of phage therapy were poorly understood (Payne
& Jansen, 2003). In the age of antibiotics these factors led to a decline in
interest in phage therapy in the West. However, research into bacteriophage
treatments continued at the Eliava Institute in Georgia. A dressing
containing a cocktail of bacteriophages is routinely used in Georgian
hospitals to prevent bacterial infection of burns (Sulakvelidze, Alavidze &
Morris, 2001).
With a renewed interest In developing alternative antimicrobials
bacteriophages have once again come into consideration. Several
approaches to exploiting bacteriophages are being investigated, including
phage therapy as discussed above, exploiting the viral endolysins and using
bacteriophage genomics to identify bacterial target proteins susceptible to
inhibition by small molecules (Liu et al., 2004). Of particular interest is the
utilisation of bacteriophage endolysins (Bradbury, 2004; Fischetti, 2001).
Bacteriophages are obligate intracellular parasites and rely on their host cell
for replication. Following replication, phage encoded endolysins are
produced to hydrolyse the bacterial cell wall causing cellular lysis from within
and the release of the progeny virions from the host, from where they can
infect new cells. Bacteriophage endolysins thus are candidates as novel
antimicrobials for treating bacterial infections. The replication cycle of
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bacteriophages is very short and the lysis of host cells occurs rapidly. Such
rapid lytic activity makes phage endolysins an attractive prospect as
candidate antimicrobials.
There are also further benefits in the use of phage endolysins as therapeutic
agents. Many bacteriophages have evolved to be highly species specific
and their endolysins may have no enzymatic effect on patients' cells thus
carrying a low risk of toxicity. Furthermore, they will also have a far lower
effect on the natural microflora of patients than current broad spectrum
antibiotics. This will help prevent conditions such as antibiotic associated
diarrhoea caused by Clostridium difficile, a key problem in administering
antibiotics to the elderly and one of increasing significance in hospitals
(Thomas, Stevenson & Riley, 2003). In 2005 there were 51,690 reported
incidences of C. difficile disease in people aged over 65 in England, a
17.2% increase on the previous year, and there is currently a significant
focus on reducing infection rates (Anon, 2006).
If phage endolysins are clinically introduced this will create a selection
pressure which may lead to S. aureus developing resistance. However, an
effective solution for overcoming any resistance would be to utilise the
mutability of the parent bacteriophage and select for phages able to cause
lysis of the adapted S. aureus. These could then be used as a source from
which new endolysins could be exploited.
Endolysins from bacteriophages of several bacterial species have been
cloned and investigated for their antimicrobial activity. A key requirement of
the endolysins, if they are to be used therapeutically, is that they are active
extracellularly, as these enzymes have evolved to degrade cell walls from
within the cell.
An early report of the activity of a recombinant phage endolysin was that of
the phage lysin genes (ply) of Listeria monocytogenes bacteriophages
(Loessner, Schneider & Scherer, 1996). These were shown to cause lysis of
heat killed L. monocytogenes cells, although assays against live cells were
not performed.
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More recently the PlyG lysin from the y phage of Bacillus anthracis has been
shown to kill both vegetative cells and germinating spores of B. anthracis
and closely related bacilli (Schuch, Nelson & Fischetti, 2002). In in vitro
assays against Bacillus cereus RSVF1, PlyG resulted in a 17,000-fold
decrease in cell viability after 20 seconds and near sterilisation after two
minutes. In a mouse model, in which RSVF1 causes death within five hours ,
administering PlyG 15 minutes post-infection had a significant effect, with 13
out of 19 mice recovering fully. Efforts made to isolate PlyG resistant RSVF1
were unsuccessful and spontaneous mutants resistant to the y phage
remained sensitive to the PlyG endolysin. Further bacteriophage derived
endolysins PlyL and PlyPH have been identified from the sequence of
B. anthracis (Low et al., 2005; Yoong et al., 2006). These endolysins also
show bacteriolytic activity with PlyL demonstrating activity against a wider
range of Bacillus species. These are encouraging results for the
development of further phage endolysin based antimicrobials.
Two phage endolysins have been identified with activity against
Streptococcus pneumoniae. Pal has been used In the prevention and
elimination of nasopharyngeal colonisation in mice (Loeffler, Nelson &
Fischetti, 2001). Cpl-1 has also been shown to be effective in eliminating
nasopharyngeal colonisation in mice, as well as prolonging survival in a
model of S. pneumoniae bacteraemia (Loeffler & Fischetti, 2003b).
Furthermore, rabbit serum raised against Cpl-1 had only a modest inhibitory
effect on the endolysin, indicating that phage endolysins could be repeatedly
administered in the treatment of infections. The Pal and Cpl-1 phage
endolysins have been shown to act synergistically in in vitro studies (Loeffler
et aI., 2003b). This synergy provides further positive encouragement in the
use of phage endolysins as potential antimicrobials
Phage endolysins have also been identified with activity against a wide
range of other species including Group B streptococci (Pritchard et al.,
2004; Cheng et al., 2005), Enterococcus faecalis and Enterococcus faecium
(Yoong et aI., 2004), and lactobacilli and lactococci (Deutsche et al., 2004).
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A number of phages of S. aureus have been studied and genes identified
which encode potential endolysins. These include phage K, P68, Twort q>11 ,
q>12 and q>13 (O'Flaherty et al., 2004; Vybiral et al., 2003; Loessner et al.,
1998; Navarre et al., 1999b; landolo et al., 2002). An endolysin from one of
these bacteriophages with activity against S. aureus, including MRSA,
would have significant potential as an antimicrobial agent. Recently there
has been further research into the endolysins of S. aureus phages. LysK is
an endolysin from the staphylococcal phage K which has a broad host
spectrum. Cell Iysates have demonstrated antimicrobial activity against a
wide range of staphylococci in in vitro studies (O'Flaherty et aI., 2005). Other
Iysins from the q>11, q>12 and P68 phages of S. aureus have been
investigated and have been shown to have in vitro activity against S. aureus
(Donovan, Lardeo & Foster-Frey, 2006b; Sass & Bierbaum, 2007; Takac,
Witte & Blasi, 2005b). These results suggest that a bacteriophage endolysin
may provide an alternative antimicrobial for the treatment of S. aureus and
that further research in the area is warranted.
1.4.3 Autolysins
Autolysins are enzymes produced by bacteria that cause hydrolysis of their
own peptidoglycan. They are believed to be found in all bacterial species
and are thought to have roles in many cellular processes including cell
growth, cell wall turnover, protein secretion and cell division (Smith,
Blackman & Foster, 2000). There must be transcriptional or post-
translational regulation of autolysins to control their activity for these
functions, as the uncontrolled expression of active enzyme could prove fatal
to the cell. This presents the opportunity to develop recombinant autolysins
as novel alternative antimicrobials. Purified recombinant autolysins could be
used as specific, highly active bacteriolytic agents.
Autolysins have been identified from several staphylococcal species and
their roles investigated. Many of these autolysins show sequence similarity,
indicating a shared evolutionary history, and function.
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The major autolysin of S. aureus is Atl (Oshida et a/., 1995; Foster, 1995).
Atl is a bi-functional enzyme with N-acetyl-muramyl-L-alanine amidase and
e n d o - ~ - N - a c e t y l g l u c o s a m i n i d a s s activity as shown in Figure 1.1 (Oshida et
al., 1995; Sugai et a/., 1995). The regions encoding the active domains are
separated by three repeat sequences which encode the cell wall targeting
domain (Baba & Schneewind, 1998b). These repeat sequence regions are
widespread, and named the LysM (lysin motif) domain (Bateman & Bycroft,
2000). The LysM domain of the AcmA autolysin of Lactococcus lactis has
been demonstrated to bind to peptidoglycan (Steen et a/., 2003). Atl has
been shown to localise to the septal ring and is thus believed to playa role
in cell division (Yamada et al., 1996). The enzymatic domains have been
shown to have bacteriolytic activity against S. aureus and
Micrococcus luteus (Oshida et a/., 1995; Sugai et a/., 1995).
AtlE is a closely related autolysin to Atl, identified in S. epidermidis
(Heilmann et al., 1997). The amino acid sequence of AtlE shares 61 0/ 0
identity with that of Atl and shows the same bi-functional modular structure,
with enzymatic regions separated by three repeat sequences. AtlE deficient
mutants form large clusters, indicating the role of the autolysin in cell
division (Heilmann et aI., 1996). AtlE also shows bacteriolytic activity when
tested against M. luteus and Staphylococcus carnosus. In addition to
peptidoglycan hydrolase activity AtlE demonstrates a strong binding activity
to the plasma protein vitronectin (Heilmann et aI., 1997). S. epidermidis is a
major nosocomial pathogen of patients with indwelling catheters and other
implanted medical devices. Host extracellular matrix and plasma proteins
rapidly coat implanted medical devices and AtlE has been demonstrated to
be involved in the attachment of S. epidermidis to polystyrene and is
essential for biofilm formation on polystyrene surfaces (Rupp et a/., 2001).
These results demonstrate that AtlE has a significant role in pathogenicity.
An understanding of the multiple roles of an autolysin is thus required before
it may be used as an antimicrobial therapy.
Another staphylococcal autolysin, Aas, with similarity to Atl has been
identified in Staphylococcus saprophyticus, a urinary tract pathogen. The
#
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amino acid sequences of the amidase and glucosaminidase active regions
of Aas show 71 °/0 identity and 66°/0 identity respectively with Atl (Hell, Meyer
& Gatermann, 1998). The cell wall targeting regions show less similarity,
with an 86 amino acid deletion in the second repeat region. Aas also has
seven repeats of 40 amino acids located N-terminal to the amidase.
However, the repeats between the active domains have been shown to be
responsible for cell targeting rather than these seven N-terminal repeats
(Hell et al., 2003). Aas has been shown to be necessary for cell cluster
dispersion and has bacteriolytic activity against heat inactivated
S. saprophyticus cells (Hell et al., 1998). Aas has also been shown to have
adhesin properties. In contrast to AtIE, Aas does not bind vitronectin, but
does bind to fibronectin and to erythrocytes. This provides further evidence
alongside that of AtlE that autolysins can have a dual function with a role in
pathogenicity as well as cell wall turnover.
Other staphylococcal autolysins that show a dual bacteriolytic and adhesin
properties include Aae of S. epidermidis, which is lytic to S. carnosus and
S. epidermidis, and binds fibrinogen, fibronectin and vitronectin (Heilmann et
al., 2003). Aae has an N-terminal three repeat sequence region homologous
to the LysM cell wall binding domain of Atl and AtIE. The hydrolytic domain
is likely to be an N-acetylmuramoyl-L-alanine amidase by homology with
Aaa/8le1 (Kajimura et al., 2005). AtlC of Staphylococcus caprae is
bacteriolytic against dried S. caprae and M. luteus cells and binds
fibronectin (Allignet et al., 2001; Allignet et al., 2002).
In addition to Atl, another autolysin of S. aureus has been identified. This
has been identified independently by Heilmann et al. and Kajimura et al.,
and designated Aaa and 81e1 respectively (Heilmann et al., 2005; Kajimura
et al., 2005). Aaa/8le1 is 76°/0 identical to Aae of S. epidermidis, has an N-
terminal LysM and a C-terminal N-acetylmuramoyl-L-alanine amidase
domain. aaalsle1 null mutants form cell clusters, indicating that the autolysin
is involved in cell separation. Double at/lsle1 mutants had significantly
impaired growth and formed irregular cell clusters (Kajimura et al., 2005).
These results indicate that Atl and 81e1 are the only peptidoglycan
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hydrolases involved in S. aureus cell separation and that SIe1 is important
for splitting the septum during cell division. sle1 null mutants also showed
reduced pathogenicity in a mouse model (Kajimura et a/., 2005). This may
be partly due to the formation of cell clusters and a reduced dissemination of
daughter cells during an infection. Aaa/Sle1 has been shown to cause
bacteriolysis to S. aureus and S. carnosus cell substrates by zymogram
analysis (Heilmann et a/., 2005). In common with the closely related Aae,
Aaa/Sle1 is able to bind fibrinogen, fibronectin and vitronectin, indicating
that it may playa role in pathogenicity beyond the necessary cell separation
(Heilmann et al., 2005).
Another staphylococcal autolysin, LytM, shares significant homology with
lysostaphin. LytM is discussed further later.
Staphylococcal autolysins therefore have multiple functions both during
cellular functions and in pathogenicity. The use of an enzybiotic based on a
staphylococcal autolysin may therefore have a profound effect on cells and
be an effective antimicrobial. In designing an enzybiotic based on autolysins
it would be necessary to eliminate the potential pathogenicity of the
autolysin, for example, by altering the binding domain to prevent binding to
plasma proteins and to address any potential immunological problems
associated with the administering of a bacterial protein.
1.4.4 Antimicrobial peptides
Many organisms produce antimicrobial peptides to inhibit the growth of
bacteria (Baba & Schneewind, 1998a). Animals and plants produce such
proteins as a defence mechanism against infection. Bacteria often produce
peptides active against closely related organisms, probably in order to gain
an advantage over species with which they are in competition within an
environment. These antimicrobial peptides provide another group of
naturally occurring proteins which could be exploited as the basis of novel
antimicrobials, and thus only prokaryotic antimicrobial peptides are
discussed further. Several antimicrobial peptides have been investigated
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including lysostaphin, enterolysin A, zoocin A and other peptides which all
share homology.
Enterolysin A is a 34.5kDa antimicrobial peptide produced by E. faecalis
(Nilsen, Nes & Holo, 2003), which shares 28% identity with lysostaphin, and
290/0 identity with zoocin A (Hickey et al., 2003). The N-terminal region of
enterolysin A is homologous to the M37 family of metallopeptidases, which
includes lysostaphin and zoocin A which have Zn2+ in the catalytic site.
Enterolysin A has been shown to target bacterial cell walls and probably
acts as an endopeptidase (Hickey et al., 2003; Nilsen et al., 2003). The C-
terminal region acts as a cell wall targeting domain and is not homologous
with lysostaphin and zoocin A. Enterolysin A is active against a broader
range of bacteria than other antimicrobial peptides, being bacteriolytic
against lactococci, pediococci, lactobacilli, listeriae and some enterococci.
Enterolysin A has previously been exploited to induce autolysis of
Lactococcus lactis, which has potential applications in the dairy industry
(Hickey, Ross & Hill, 2004). The broad range of the cell wall targeting
domain of enterolysin A could be exploited as part of a novel enzybiotic.
This would enable the development of a broader spectrum antimicrobial
than would be possible with more specific antimicrobial peptides.
Zoocin A is an antimicrobial peptide identified from Streptococcus equt
subspecies zooepidemicus strain 4881 (Simmonds et al., 1995). Zoocin A
has bacteriolytic activity against other S. equi ssp. zooepidemicus strains,
Streptococcus pyogenes, Streptococcus gordonii and Streptococcus
mutans. It is a cell wall hydrolytic enzyme with endopeptidase activity
(Simmonds et a/., 1996). Zoocin A has been shown to be a penicillin binding
protein, indicating that it is a o-alanyl endopeptidase active against the di- or
tri-alanine cross-bridges of streptococcal peptidoglycan (Heath et al., 2004).
Zoocin A is a 30kDa modular protein, with an N-terminal catalytic domain
homologous to that of lysostaphin and a C-terminal domain responsible for
cell wall binding which shows limited homology with lysostaphin's C-terminal
binding domain (Simmonds, Simpson & Tagg, 1997; Lai, Tran & Simmonds,
2002; Liang, Simmonds & Timkovich, 2004). The host S. equi ssp.
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zooepidemicus strain carries a zoocin A immunity factor (zit) gene which
protects itself against the activity of the antimicrobial peptide (Beatson,
Sloan & Simmonds, 1998). Zoocin A therefore represents an antimicrobial
peptide with a different spectrum of activity to both enterolysin and
lysostaphin. These differences may be of interest in the development of
enzybiotics active against S. aureus and other species.
Other antimicrobial peptides showing homology to lysostaphin have been
identified in a range of species. E. coli produces MepA, a metallopeptidase
with a homologous active site containing a Zn2+ ion that is involved in cell
wall turnover (Marcyjaniak et al., 2004). YibP, also named EnvC, is another
E. coli zinc metallopeptidase with multiple cellular functions (Ichimura et al.,
2002; Hara et al., 2002). Millericin B is an endopeptidase produced by
Streptococcus milleri which cleaves peptidoglycan stem peptides and cross-
bridges (Beukes et al., 2000). The catalytic milB gene shares 36% identity
with the lysostaphin gene at the DNA sequence level, with the protein
sequences of their gene products sharing 62% identity (Beukes & Hastings,
2001 ).
ALE-1 IS a close lysostaphin homologue produced by Staphylococcus
capitis EPK1. It has bacteriolytic activity against S. aureus although it is
inactive against S. capitis. It is a glycyl-glycine endopeptidase which cleaves
peptidoglycan cross-bridges. ALE-1 share 50% overall identity with
lysostaphin at the DNA sequence level, and 83% amino acid sequence
identity of the C-terminal targeting domains (Sugai et al., 1997a; Lu et al.,
2006). The crystal structure of the targeting domain has been elucidated (Lu
et al., 2006).
LytM is a peptidoglycan hydrolase of S. aureus, which has been shown to
have autolytic activity, in addition to the autolysins Atl and Sle1/Aaa
discussed previously (Ramadurai & Jayaswal, 1997). LytM is a 32kDa
protein, with a C-terminal domain sharing 51 % identity at the amino acid
level with the N-terminal endopeptidase domain of lysostaphin. LytM is
bacteriolytic against S. aureus and S. carnosus acting as a glycyl-glycine
endopeptidase (Ramadurai et al., 1997; Ramadurai et al., 1999). LytM is
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another zinc metallopeptidase, and the crystal structures of the latent and
active forms of the protein have been determined (Odintsov et al., 2004;
Firczuk, Mucha & Bochtler, 2005).
There are a wide range of antimicrobial peptides which have been
characterised. They display a range of specificities for different organisms
and a number of target cleavage sites. Many of these may be suitable for
the development of enzybiotics as novel antimicrobials. In addition to the
antimicrobial peptides described above lysostaphin has been the subject of
particular interest as an alternative antimicrobial, providing a paradigm for
further studies, and is subsequently discussed in greater detail.
1.5 LYSOSTAPHIN
1.5.1 The discovery of lysostaphin
Lysostaphin was originally discovered by Schindler and Schuhardt in 1964.
During transduction studies with staphylococci, a colony exerting a lytic
effect on the surrounding S. aureus lawn was observed (Schindler &
Schuhardt, 1964). Possible bacteriophage activity was excluded and the
responsible protein was named lysostaphin. This protein was bacteriolytic
against over 50 staphylococcal strains, but inactive against organisms from
other genera. Lysostaphin is produced by the organism formerly known as
Staphylococcus staphylolyticus, now designated S. simulans biovar
staphylolyticus (Sloan, Robinson & Kloos, 1982). It is a glycyl-glycine
endopeptidase active against the peptidoglycan cross-bridges of nearly all
other staphylococcal species (Schindler & Schuhardt, 1965; Browder et al.,
1965; Zygmunt, Browder & Tavormina, 1967). Lysostaphin was identified as
a zinc containing enzyme of around 25kDa, with an isoelectric point of 9.5
and a pH optimum of 7.5 (Browder et al., 1965; Trayer & Buckley, 1970).
16

1.5.3 The structure of mature lysostaphin
The active mature lysostaphin is a 246 aa peptide with a mass of
approximately 27kDa. It has a modular structure consisting of an N-terminal
catalytic domain and a 92 aa C-terminal cell wall targeting domain (Thumm
et a/., 1997) (Figure 1.2). The crystal structure of lysostaphin has not yet
been elucidated. However, structures of the active form of LytM and the cell
wall targeting domain of ALE-1, close homologues of lysostaphin, have
been reported and indicate possible structural features of lysostaphin
(Firczuk et a/., 2005; Lu et a/., 2006).
1.5.4 The lysostaphin targeting domain
Lysostaphin is highly specific for staphylococci. It acts rapidly against
S. aureus, more slowly against other staphylococcal species and is inactive
against non-staphylococci (Schindler et al., 1964). The C-terminal 92 aa of
mature lysostaphin have been shown to be responsible for the targeting of
the peptide to staphylococcal cell walls with approximately 106 receptors for
the targeting domain on the surface of each S. aureus cell (Saba &
Schneewind, 1996). Recently, a study investigating the binding of green
fluorescent protein (GFP) tagged targeting domain to S. aureus cell walls
and purified peptidoglycan has been reported (Grundling & Schneewind,
2006b). This demonstrates that exopolysaccharides, cell surface proteins,
lipoproteins and teichoic acids, all components of the cell wall architecture,
are not required for binding of the targeting domain to staphylococcal cells.
Interestingly pentaglycine cross-bridges, the substrate for the
endopeptidase, were found to be essential for cell wall binding. However,
the addition of excess pentaglycine did not inhibit binding of the cell wall
targeting domain. This indicates that the lysostaphin targeting domain binds
to structural features of pentaglycine cross-linked peptidoglycan. It has not
been determined whether the pentaglycine cross-bridge involved In
targeting domain binding is also the substrate for the endopeptidase, or
whether adjacent cross-bridges become substrate molecules.
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The targeting domain of lysostaphin has been classified as an SH3b
domain, a homologue of the src homology 3 (SH3) domain (Lu et al., 2006).
The SH3b domain in prokaryotes is believed to mediate the attachment of
proteins to bacterial cell walls (Ponting et al., 1999). The targeting domain of
ALE-1 is another SH3b family member and has targeting activity to
S. aureus. The targeting domain of ALE-1 is a close homologue of
lysostaphin's with 83% identity at the amino acid level and therefore
probably binds to the same surface receptor (Sugai et a/., 1997a). The three
dimensional structure of a FLAG tagged ALE-1 targeting domain has been
solved and consists of eight ~ - s t r a n d d as shown in Figure 1.3 A (Lu et a/.,
2006). This resembles the tertiary structure of eukaryotic SH3 domains
although there are significant differences. The ALE-1 targeting domain is 30
aa larger than typical SH3 domains, and has an additional ~ - s t r a n n and
other differences which block the binding groove of the SH3 substrate
(Figure 1.3 B). These differences constitute a deep and narrow groove that
can potentially accommodate a penta or hexapolypeptide, with the shape of
the groove revealing a preference for glycine (Lu et a/., 2006) (Figure 1.4).
The structure of the SH3b domain of ALE-1 appears to be adapted to fit the
pentaglycine cross-bridges of S. aureus. Alterations to peptidoglycan cross-
bridges would severely impair the binding of the ALE-1 targeting domain.
The conserved tryptophan residue at position 358 is not located in the
groove, although a W358A mutant reduced peptidoglycan binding by half,
indicating a potential role for this region in substrate binding, possibly to
another structural feature of peptidoglycan (Lu et a/., 2006). This provides
further evidence that the targeting domains of ALE-1 and lysostaphin bind to
pentaglycine cross-linked peptidoglycan, requiring both the cross-bridge and
an additional structural feature of the S. aureus peptidoglycan.
19


1.5.5 The lysostaphin endopeptidase domain
The N-terminal domain of mature lysostaphin is a zinc-metalloprotease
active against the pentaglycine cross-bridges of susceptible staphylococci
(Browder et al., 1965; Zygmunt et al., 1967; Sloan, Smith & Lancaster,
1977). Glycylglycine endopeptidase activity has been demonstrated against
a hexaglycine substrate, as well as against staphylococcal peptidoglycan
(Kline, de la Harpe & Blackburn, 1994). Against a synthetic pentaglycine
substrate the endopeptidase is able to cleave between any of the
glycylglycine bonds. However, against staphylococcal peptidoglycan
cleavage occurs predominantly between residues three and four, and
between glycines two and three (Navarre & Schneewind, 1999a;
Schneewind, Fowler & Faull, 1995; Warfield et al., 2006). The cleavage of
staphylococcal peptidoglycan cross bridges disrupts the integrity of the cell
wall, with the high internal osmotic pressure causing cell lysis and death.
LytM is a S. aureus autolysin with homology to lysostaphin, that is believed
to also have glycylglycine endopeptidase activity (Ramadurai et aI., 1999).
The crystal structure of full length LytM has been solved, although this form
of the enzyme has been shown to be inactive (Odintsov et al., 2004). LytM
may also be processed extracellularly and the structure of active truncations
has also been determined (Firczuk et aI., 2005). LytM is also a bimodular
protein. It has a C-terminal domain with highly conserved regions among
lysostaphin-like proteins and an N-terminal domain with little similarity to
other related proteins (Figure 1.5). The C-terminal domain contains the Zn2+
binding ligands anchored onto a central, six stranded anti-parallel ~ - s h e e e
(Odintsov et al., 2004). These ligands are histidine 210, aspartate 214 and
histidine 293 as numbered in the sequence of full length LytM (Firczuk et al.,
2005) (Figure 1.6). Mutations of these residues results in the loss of activity
of LytM, demonstrating their importance (Odintsov et aI., 2004). A
phosphate acts as the fourth ligand, tetrahedrally co-ordinating the Zn2+ in
the active site of the enzyme (Firczuk et al., 2005). Histidine 293 is the
second histidine in a highly conserved HXH motif. The first histidine of this
motif although not involved in co-ordinating Zn2+ is essential for LytM activity
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1.6 THE THERAPEUTIC POTENTIAL OF LYSOSTAPHIN
As a highly specific anti-staphylococcal agent lysostaphin has been the
subject of extensive investigations as a potential antimicrobial agent. Early
studies demonstrated that it could be effective in treating S. aureus
infections. Recently, with a renewed interest in developing alternative
antimicrobials, lysostaphin has been the subject of further research.
1.6.1 Early lysostaphin trials
Shortly after its discovery lysostaphin was shown to be effective against 20
clinical isolates of S. aureus. These isolates were all resistant to penicillin G
and ampicillin, and showed reduced susceptibility to methicillin. No
incidence of lysostaphin resistance was observed and lysostaphin was
found to be effective at lower concentrations than traditional antibiotics
(Zygmunt, Harrison & Browder, 1965). Lysostaphin was also shown to be
equally effective against the newly emerging threat of MRSA (Zygmunt et
al., 1968b). Investigations revealed that coagulase negative staphylococci
showed variable susceptibility to lysostaphin, possibly due to differences in
cell wall composition (Zygmunt, Browder & Tavormina, 1968a).
Early studies also demonstrated that lysostaphin could be used successfully
to treat mice given intraperitoneal injections with S. aureus (Schuhardt &
Schindler, 1964). These results indicated that lysostaphin could be an
effective therapeutic agent against S. aureus including MRSA. This was
further supported by results demonstrating that human sera and red blood
cells had a minimal antagonistic effect on the action of lysostaphin against
S. aureus (Zygmunt, Browder & Tavormina, 1966b; Zygmunt, Browder &
Tavormina, 1966a). Lysostaphin was subsequently used In more
sophisticated animal studies being effective in a model of S. aureus
endocarditis in dogs and as a combined treatment with methicillin in the
treatment of established staphylococcal abscesses in mice (Goldberg et al.,
1967; Dixon, Goodman & Koenig, 1968). Lysostaphin was also used in a
mouse model of renal S. aureus infection where it was effective in
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controlling the staphylococcal population of kidneys, reducing the mortality
rate, and clearing high numbers of kidneys of infection (Harrison & Zygmunt,
1967).
Lysostaphin was also used in early human trials. Systemic lysostaphin
treatment was showed to have an antimicrobial effect in a neutropoenic
patient (Stark et aI., 1974). The patient had developed MRSA pneumonia
and abscesses and had failed to respond to three weeks of anti-
staphylococcal antibiotics. The patient was treated with a single intravenous
dose of lysostaphin and experienced only a brief episode of flushing,
hypotension, and tachycardia which was subsequently resolved. The patient
died three days after lysostaphin treatment of progressive heart failure. The
post-mortem revealed no evidence of staphylococcal infection, and
previously infected sites were culture negative.
Lysostaphin was also investigated in a nasal spray and was shown to
reduce the carnage rate of persistent S. aureus carriers within an
institutional environment. This effect lasted up to eleven days after a five
day treatment and indicated that lysostaphin could play a role in the
clearance of S. aureus from a patient over the period of a hospital procedure
(Quickel et a/., 1971). Other studies showed varying lengths of clearance of
S. aureus following intranasal application in medical staff and in paediatric
patient carriers (Martin & White, 1968; Harris, Nunnery & Riley, 1967). No
immunological hypersensitivity was observed in these trial subjects, with the
largest study only identifying a single wheal and flair reaction in one person
after topical lysostaphin application, which had subsided within two hours
post-exposure (Quickel et a/., 1971).
Although the results of these and other studies indicated that lysostaphin
was a promising novel antimicrobial active against MRSA it was not at the
time further developed as a therapeutic agent and clinically introduced.
Reasons for this included the availability of effective anti-staphylococcal
antibiotics, fears over the immunological response to a parentally
administered protein antimicrobial, and problems with the purity of the
available lysostaphin preparations (Climo et a/., 1998).
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1.6.2 Renewed interest in lysostaphin
As techniques of producing recombinant proteins of high purity have been
developed and as S. aureus has shown an increasing pattern of resistance
to traditional antibiotics, the potential therapeutic value of lysostaphin has
been re-evaluated.
Recent studies have tested the activity of recombinant lysostaphin against
clinical isolates of S. aureus. A collection of 429 isolates was taken from
German hospitals includlnq 210 cultures from nasal swabs and 219 from
patients with S. aureus bacteraemia. All isolates were susceptible to
lysostaphin, with no difference observed between isolates from nasal
carriage or from patients with bacteraemia, and no difference observed
amongst the 23 isolates that were methicillin resistant (von Eiff et a/., 2003).
A separate survey of 257 isolates from hospital patients in Beijing, China,
also found all isolates of MRSA and methicillin sensitive S. aureus were
susceptible to recombinant lysostaphin (Yang et a/., 2007).
The activity of lysostaphin has been investigated in several models of
staphylococcal infection. A rabbit model of MRSA endocarditis was used to
investigate the potential of lysostaphin, due to the frequent failure of
vancomycin in treating such infections (Climo et a/., 1998). Lysostaphin was
shown to retain bactericidal activity in rabbit serum, and was well tolerated,
although some inhibition of activity by antibody production was observed. A
single dose of lysostaphin caused an equal reduction in bacteraemia to
vancomycin treatment, and following both, all animals were culture positive
after 30 hours. However, in a three day treatment regime lysostaphin proved
more effective than vancomycin, sterilising 91 % of aortic valve vegetations.
This was the highest reported clearance rate of any single agent therapy.
Lysostaphin was also found to be effective in treating VISA vegetations,
sterilising 830/0 in the rabbit endocarditis model (Patron et a/., 1999).
Lysostaphin was less effective in the treatment of S. epidermidis in this
model. However, lysostaphin was found to act synergistically with the ~ ~
lactam nafcillin in the rabbit endocarditis model against oxacillin resistant
S. epidermidis (Kiri, Archer & Climo, 2002). The combination of lysostaphin
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and nafcillin was as effective as vancomycin alone and significantly better
than lysostaphin or nafcillin alone, and could provide a useful combination
therapy in the event of vancomycin treatment failure.
Lysostaphin has been demonstrated to be effective in the elimination of
MRSA in rabbit models of keratitis and endophthalmitis, both conditions
which can lead to blindness (Dajcs et al., 2000; Dajcs et aI., 2001).
Resistance to the current antibiotic treatments is increasing amongst MRSA
isolates. Lysostaphin was more effective than any other single agent,
inclUding vancomycin, at sterilising rabbit corneas in the keratitis model
(Dajcs et al., 2000). The effect of immunisation against lysostaphin in these
models was also investigated (Dajcs et al., 2002). Antibodies were raised in
rabbits by subcutaneous, intranasal or topical exposure. Only following
subcutaneous exposure was serum at a high titre able to inhibit the anti-
staphylococcal activity of lysostaphin in vitro. Lysostaphin was effective in
eliminating MRSA from rabbits previously exposed to it by all three routes in
both models of eye infection, although a reduction in damage caused by
disease was not observed. No adverse effects were observed in any rabbits
exposed to lysostaphin by all three routes, or by treatment in the models of
infection (Dajcs et aI., 2002).
Further in vivo studies have been carried out to investigate the potential of
lysostaphin in veterinary medicine. Staphylococcal mastitis is the most
prevalent disease of diary cattle. An early study showed that lysostaphin
had some effect in the treatment of cattle infected with S. aureus and that
improved lysostaphin formulations may have useful therapeutic potential
(Oldham & Daley, 1991). In a mouse model, the expression of lysostaphin in
the mammary glands of transgenic animals conferred resistance to
staphylococcal mastitis (Kerr et al., 2001). Subsequently, transgenic cattle
carrying a mammary specific transgene encoding lysostaphin have also
been shown to be resistant to infection by S. aureus. All six lines from these
transgenic animals also express lysostaphin, including three founded by
bulls (Wall et al., 2005; Donovan, Kerr &Wall, 2005).
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Nasal carriage is a key risk factor in infections by S. aureus, particularly in
the hospital environment. Rates of infection are higher in carriers than non-
carriers, and individuals are usually infected with their own carriage isolates
(Peacock, de Silva & Lowy, 2001). The eradication of S. aureus nasal
carriage in high risk individuals could therefore reduce the incidence of
infections. This could have a particular role in the prevention of post-surgery
wound infections by S. aureus. Mupirocin has been used to reduce nasal
colonisation, but resistance to this agent is developing. Lysostaphin could
be an effective alternative to eliminate nasal carriage in such patients. A
cotton rat model of S. aureus colonisation of the anterior nares has been
used to demonstrate the efficacy of lysostaphin in clearing nasal carriage
(Kokai-Kun et al., 2003). A cream formulation of lysostaphin was used in
rats inoculated with the MRSA MBT5040 strain. A single dose of lysostaphin
eradicated S. aureus in 93% of animals, and nasal colonisation was
eradicated in all animals with a dosing regime of three doses over three
days. Lysostaphin was tested against two MSSA strains, two MRSA and
one mupirocin resistant S. aureus strain. All strains were sensitive to
lysostaphin which was more effective than mupirocin, and nasal clearance
lasted at least one week. No lysostaphin resistant S. aureus colonies were
isolated, even when lysostaphin was added at sub-inhibitory concentrations.
An improved cream formulation was subsequently reported to extend the
nasal residency of lysostaphin (Walsh et aI., 2004). Lysostaphin remained in
the anterior nares at inhibitory concentrations for at least 24 hours. In the
clinical setting this cream could be applied daily and maintain lysostaphin
above sub-inhibitory concentrations for the duration of a patient's hospital
stay.
S. aureus is a major nosocomial pathogen of those with indwelling medical
devices. Biofilms consisting of a multilayered community of sessile cells and
an extracellular matrix often forms on the surface of such devices, which
then acts as a source of further infections. Biofilms are often difficult to treat
due to increased antibiotic resistance of cells in a biofilm, poor access to
cells, and a slow growth rate once formed (Donlan & Costerton, 2002; Patel,
2005).
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Lysostaphin has been shown to disrupt and eradicate S. aureus biofilms
growing on polystyrene, polycarbonate and glass surfaces (Wu et al., 2003).
A rapid effect is seen, with a measurable disruption of the biofilm within 20
minutes, making lysostaphin treatment faster and more effective than
treatment with oxacillin or vancomycin. Lysostaphin was also able to disrupt
S. epidermidis biofilms growing on glass, although it had no affect on
Pseudomonas aeruginosa. The mode of action of lysostaphin against
S. aureus biofilms is not known, although it is suggested that there is
sufficient lysis of sessile cells caused to destabilise the biofilm (Wu et al.,
2003). These results indicate that lysostaphin could be used in the
eradication of biofilms from patients with indwelling medical devices.
Lysostaphin has also been investigated for its potential to prevent the
colonisation of catheters by S. aureus (Shah, Mond & Walsh, 2004).
Lysostaphin was coated onto polystyrene and FEP polymer surfaces that
are used in catheters, washed with phosphate buffered saline and then
challenged with S. aureus. There was a 99.5% reduction in the bacterial
count from lysostaphin-coated surfaces compared to untreated surfaces
following bacterial challenge. Increased coating time led to increased killing
activity up to an optimum time of 15 minutes, indicating that bound
lysostaphin was responsible for the anti-staphylococcal activity. Lysostaphin
retained activity against S. aureus for 96 hours with a change in buffer every
24 hours, indicating that a coated catheter could be used to prevent biofilm
formation and protect a patient for several days. The presence of human
serum had no adverse affect on the activity of lysostaphin coated to the
surface. Lysostaphin coated polymers proved effective at preventing biofilm
formation by several S. aureus strains including MRSA, and had significant
activity against S. epidermidis (Shah et al., 2004). These results
demonstrate that as well as having potential as a treatment for biofilms
growing on polymer surfaces, lysostaphin coated catheters could also be
useful in preventing the colonisation of those devices.
As lysostaphin has been shown to have potential uses in the treatment of
several staphylococcal infections work has also been carried out to improve
the formulation of the protein, and to devise large scale production systems
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that would be required for the clinical introduction of lysostaphin. One
drawback in using lysostaphin as an intravenous treatment is the relatively
short half life of the drug. One approach to resolving this has been to
conjugate lysostaphin to polyethylene glycol (PEG) (Walsh, Shah & Mond,
2003). This reduces renal ultrafiltration by increasing the molecular size, and
creates a molecular shield which can block access to antibodies. The PEG
conjugated lysostaphin has slightly lower enzymatic activity than
unconjugated protein, but in a mouse model the serum half life was
extended from 1 hour to 24 hours, increasing the plasma drug
concentration. The prolonged persistence of PEG conjugated lysostaphin,
and its reduced antibody binding, enhance the therapeutic value of
lysostaphin as an intravenous treatment.
Industrial scale production of lysostaphin has been achieved using the nisin-
controlled gene expression system (NICE) in Lactococcus lactis (Mierau et
al., 2005a). A large scale culture of 3000L was grown, the cell filtrate
collected and the protein purified by cation-exchange chromatography. The
initial fermentation yielded 100mg L-1 of which 40% was recovered after
downstream processing providing 120g from the 3000L fermentation.
Although this is a fairly low yield for a bulk production the process has been
further optimised on a small scale and could be used in an industrial scale
production process (Mierau et al., 2005b). Lysostaphin from the
fermentation process described by Mierau et al (2005a) was used in
subsequent phase I clinical trials.
1.6.3 Lysostaphin in clinical trials
Lysostaphin has been developed as a candidate therapeutic agent by
Biosynexus Incorporated, a U.S. biotechnology company. It has been
formulated as a topical anti-staphylococcal cream to eradicate S. aureus
nasal carriage. Biosynexus have announced that their compound,
BSYX-L210, has successfully completed phase I and phase 1/11 clinical trials
to assess its safety and as an initial study of its efficacy (Anon, 2003). The
phase I trial involved 18 volunteers including 7 S. aureus carriers. Four of
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the carriers were completely cleared of S. aureus following treatment with
BSYX-L210, whilst three carriers receiving a placebo remained unaffected.
No significant adverse events were observed. Full details of the phase 1/11
trial and its results have not yet been described, although it is reported to
validate results of pre-clinical studies in the cotton rat model (Kokai-Kun et
al., 2003). These results are encouraging for the further development of
lysostaphin as a novel antimicrobial agent.
1.7 RESISTANCE TO LYSOSTAPHIN
The future clinical application of lysostaphin will introduce a selection
pressure for the evolution of S. aureus mutants resistant to the antimicrobial
peptide. This could occur through one of several possible mechanisms
either blocking targeting of the peptide to staphylococcal peptidoglycan, or
by altering the target of the endopeptidase. Lysostaphin resistant S. aureus
mutants have previously been isolated in both in vitro and in vivo studies
(Zygmunt et al., 1967; Climo, Ehlert &Archer, 2001).
1.7.1 Host immunity to lysostaphin
S. simulans biovar staphylolyticus protects itself from the actions of
lysostaphin by two mechanisms. The first is to express a propeptide with
reduced lytic activity, which is only processed to the active, mature peptide
extracellularly as described previously. It has been shown that this
processing step is a significant contributory factor in the conferring of host
resistance to recombinant S. carnosus (Thumm et al., 1997).
Secondly, S. simulans biovar staphylolyticus produces a lysostaphin
immunity factor (Lif) protein. The /if gene, also known as epr (endopeptidase
resistance gene), is located on the pACK1 plasmid which had been shown
to be required for lysostaphin resistance (DeHart et al., 1995; Thumm et al.,
1997). The /if gene contains 413 codons and is transcribed in the opposite
direction to the Iss gene from which it is separated by a 208 non coding
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base pair sequence (Thumm et al., 1997). When S. aureus RN4220 is
transformed with the Iss and /if genes it produces and is resistant to
lysostaphin (DeHart et al., 1995). Lif was found to protect S. simulans biovar
staphylolyticus by modifying the peptidoglycan cross-bridges, incorporating
serine in place of glycine residues (DeHart et al., 1995; Thumm et aI., 1997).
Early studies on the susceptibility of coagulase negative staphylococci had
previously shown that species with an increased presence of serine, at the
expense of glycine, showed a reduced sensitivity to lysostaphin (Zygmunt et
al., 1968a).
The Lif protein is homologous to the FemAlS proteins of S. aureus. These
proteins are responsible for the stepwise addition of glycine residues to
staphylococcal peptidoglycan cross-bridges (Thumm et aI., 1997). The
expression of Lif leads to the specific incorporation of serine residues at
positions three and five of the cross-bridge (Ehlert et al., 2000). However, Lif
does not extend the interpeptide bridge, and FemA and FemS are still
required for the cross-bridge formation. The interaction of Lif with FemA and,
or FemS is thought to lead to the substitution of glycine with serine at these
positions (Ehlert et al., 2000). Lysostaphin has been shown to be unable to
hydrolyse glycylserine or serylglycine bonds (Robinson, Hardman & Sloan,
1979). Therefore the expression of Lif protects the host organism from the
enzymatic action of lysostaphin. Furthermore, as pentaglycine cross-linked
peptidoglycan is believed to the receptor for the targeting domain of
lysostaphin (Grundling et al., 2006b; Lu et al., 2006), Lif may have a dual
protective effect inhibiting the binding of lysostaphin as well as the
endopeptidase action.
Thumm and G6tz (1997) suggest that S. simulans biovar staphylolyticus
acquired the Iss and /if genes through a horizontal gene transfer event. It
remains possible that following the clinical introduction of lysostaphin, that
S. aureus develop resistance by acquisition of the lif gene. A plasmid from
S. sciurii strain DD4747 has been identified carrying a gene similar to /if and
recombinant S. aureus RN4220 expressing this gene have a greater cell
wall serine content and an increased resistance to lysostaphin (Heath et al.,
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2005). This provides further evidence that such genetic transfers have
previously occurred, and that there is another source of the /if gene which
could become transferred to S. aureus in the clinical environment in the
future. This would compromise the therapeutic value of lysostaphin, and
should be considered in the development of lysostaphin based
antimicrobials.
Fortunately the presence of the /if gene in S. aureus is reported to increase
susceptibility to methicillin (DeHart et al., 1995). Any infections caused by
lysostaphin resistant mutants arising this way could therefore be simply
treated with nafcillin. The co-administration of nafcillin with lysostaphin could
prevent resistance developing through the acquisition of /if. However, if such
mutants were able to develop nafcillin resistance in the future, they would
pose a significant clinical threat.
1.7.2 Resistance to lysostaphin by shortened cross-bridges
Resistant S. aureus mutants have been isolated in both in vitro and in vivo
studies following exposure to sub-inhibitory concentrations of lysostaphin
(Climo et al., 2001; Kusuma et al., 2007). The isolates from both studies had
shortened peptidoglycan cross-bridges.
The pentaglycine cross-bridge of staphylococci is formed by a sequential
process involving several proteins. FmhB is involved in the addition of the
first glycine residue to the stem peptide (Rohrer et al., 1999). Glycines two
and three are then added by the action of FemA (Kopp et al., 1996;
Stranden et al., 1997). Finally, FemB is responsible for the addition of
glycines four and five (Henze et al., 1993). Mutation of femB results in a
triglycine cross-bridge and femA mutations lead to a monoglycine cross-
bridge.
The lysostaphin resistant mutants isolated both had femA mutations,
resulting in monoglycine cross-bridges (Climo et al., 2001; Kusuma et al.,
2007). This mutation confers resistance to lysostaphin by removing the
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enzymatic target of the glycylglycine endopeptidase and also by altering the
structure of the receptor site of the targeting domain.
From the studies carried out to date, the emergence of femAiB mutations is
likely to be the most common form of resistance that may emerge following
the clinical introduction of lysostaphin. In a rabbit model of endocarditis
caused by oxacillin resistant S. aureus treated with a low dose of
lysostaphin, resistant isolates were found after three days (Climo et al.,
2001). However, lysostaphin resistant mutants that have been isolated show
a loss of resistance to ~ - I a c t a m s s The co-administration of lysostaphin with
~ - I a c t a m m in vitro prevented the emergence of lysostaphin resistance, and a
joint lysostaphin and nafcillin therapy in the rabbit endocarditis model also
prohibited resistance developing (Climo et al., 2001).
Null femAB mutants of S. aureus have previously been shown to be
hypersensitive to methicillin (Stranden et al., 1997). It is thought that this is
due to the substrate requirement of PBP2' being incompatible with the
reduced peptidoglycan cross-bridge (Climo et al., 2001). As well as having
shortened cross-bridges femAB null mutants also had a reduced number of
peptidoglycan cross-bridges, which is thought to explain their increased
sensitivity to ~ - I a c t a m m (Stranden et al., 1997).
Furthermore, lysostaphin resistant femA mutants also show a reduced
fitness compared with their parent S. aureus strains. They demonstrate an
impaired exponential growth rate and are out-competed by wild-type
S. aureus (Stranden et al., 1997; Kusuma et al., 2007). They are also more
susceptible to elevated temperatures and have been shown to be at least
fivefold less virulent in a mouse model of kidney infection (Kusuma et al.,
2007). These mutants failed to develop compensatory mutations to restore
fitness during a 14 day serial passage without selective pressure.
It therefore seems likely that lysostaphin resistant femAiB mutants do not
pose a serious clinical threat and could easily be prevented in the hospital
setting through combination therapy with another antibiotic. Lysostaphin
also is reported to have a synergistic lytic activity in combination with ~ ~
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lactams, providing a dual therapeutic benefit to such a treatment (Climo et
a/., 2001). However, there is currently no selective pressure in the hospital
environment for the emergence of a methicillin, lysostaphin resistant
S. aureus. If lysostaphin is introduced as a new antimicrobial such mutants
may emerge and this event should be considered in the development of
future lysostaphin based treatments.
1.7.3 Lysostaphin resistance in VISA
Lysostaphin resistance has been observed In vancomycin intermediately
sensitive S. aureus strains, including clinical isolates. In one study six
S. aureus blood cultures were taken from a patient receiving vancomycin
therapy over a period of 16 days (Boyle-Vavra, Carey & Daum, 2001).
Initially isolates were glycopeptide susceptible, but as the bacteraemia
continued the vancomycin MIC increased. As vancomycin intermediate
sensitivity developed the MIC of lysostaphin increased. This result concurs
with VISA strains developed in vitro, although not all VISA strains showed
increased resistance to lysostaphin (Pfeltz et a/., 2000; Boyle-Vavra et a/.,
2001). This clinical VISA isolate had increased levels of peptidoglycan
cross-linking. The composition of the cross-bridges was unaffected,
indicating that the increased cross-linking may be responsible for the
increase in the lysostaphin MIC. It is suggested that this could be due to the
increased number of target sites for lysostaphin requiring a higher
concentration to achieve the same lytic effect. However, it was noted that a
VISA strain with a very high level of peptidoglycan cross linking had a low
MIC of lysostaphin (Boyle-Vavra et a/., 2001).
A separate study characterising glycopeptide intermediately sensitive
S. aureus has shown lysostaphin resistance in strains with reduced levels of
peptidoglycan cross-linking (Koehl et a/., 2004). Again this strain shows no
evidence of having shortened cross-bridges or any serine substitutions.
Conversely peptidoglycan purified from this strain is highly sensitive to
lysostaphin. It is suggested that the increased lysostaphin resistance may
be related to defective autolysis in GISA strains, and that autolysins are
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involved in the lysis caused by lysostaphin treatment (Koehl et al., 2004).
There is some evidence that atl null mutants show increased resistance to
lysostaphin (Pfeltz et al., 2000).
The emergence of lysostaphin resistant VISA strains in the clinical setting
could lead to the failure of lysostaphin as a therapeutic agent. This
mechanism of resistance is poorly understood, but efforts should be made
to counteract its clinical emergence.
1.7.4 Other potential resistance mechanisms
Bacteria have evolved many different methods of evading the action of
traditional antibiotics. The mechanisms described above have all been
previously identified through in vivo and in vitro studies. Other mechanisms
may evolve once the selection pressure of clinically administered
lysostaphin is introduced.
A lysostaphin resistant mutant has been generated in a study of transposon
mutants (Grundling, Missiakas & Schneewind, 2006a). Characterisation of
the mutant identified that the transposon had inserted into a previously
uncharacterised gene, subsequently named lysostaphin resistance A (lyrA).
The inactivation of lyrA caused high level resistance to lysostaphin through
apparently minor alterations to peptidoglycan structure. LyrA is predicted to
be a multispanning membrane protein and contains an Abi domain. Abi
containing proteins are metallo-dependent membrane proteases, although
protease activity in LyrA does not seem to be required for lysostaphin
resistance (Grundling et al., 2006a). No change in lysostaphin targeting
domain binding was observed to lyrA mutants, indicating that resistance is
due to a non-peptidoglycan related attribute of S. aureus. Importantly lyrA
mutants do not show a decrease in ~ - I a c t a a resistance. If this resistance
mechanism were to emerge in the hospital environment it would seriously
compromise the therapeutic potential of lysostaphin.
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Other resistance mechanisms that have not yet been observed could also
emerge and threaten the efficacy of lysostaphin. The cellular receptor of
lysostaphin is not fully understood, but is thought to be a structural feature of
pentaglycine cross-linked peptidoglycan (Grundling et al., 2006b; Lu et al.,
2006) Alterations to the cross-bridges have been shown to lead to
lysostaphin resistance and other changes to the peptidoglycan structure
could also lead to resistance emerging.
1.8 THE DEVELOPMENT OF SECOND GENERATION LYSOSTAPHINS
Results of in vitro and in vivo studies and of clinical trials provide
encouragement that lysostaphin may be successfully introduced as a novel
antimicrobial treatment for staphylococci including MRSA. However, once
clinically introduced there will be a significant selection pressure for the
evolution of lysostaphin resistant MRSA. This may occur by one or more of
the several mechanisms discussed above and experience of traditional
antibiotics suggests that this event is likely to occur at some point in time.
This event may be delayed by the co-administration with other antibiotics,
and by prudent prescription of lysostaphin. The likelihood of this event also
justifies the investigation of second generation lysostaphin treatments.
These second generation molecules should be developed with the aim of
overcoming the likely resistance mechanisms that may evolve. Furthermore,
they may also be designed to have a wider range of therapeutic
applications, such as a broader spectrum of activity or have improved
pharmacokinetics properties. Second generation lysostaphins may be
developed by designing synthetic variations. Synthetic peptides based on
the active site of insect defensins have been demonstrated to protect mice
from a lethal MRSA challenge (Saido-Sakanaka et al., 2005). Alternatively
second generation lysostaphins may utilise features of other peptidoglycan
hydrolases in the form of an enzybiotic. A lysostaphin based enzybiotic
could incorporate features of bacteriophage endolysins, staphylococcal
autolysins or other antimicrobial peptides previously discussed.
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1.8.1 Exploiting the modular domain of lysostaphin
Lysostaphin and the other peptidoglycan hydrolases previously described
are modular enzymes with discrete cell wall targeting and catalytic domains.
This domain structure could be utilised in the development of second
generation lysostaphin based enzybiotics by SUbstituting either domain with
that from another antimicrobial peptide. Such a chimeric peptide could be
expected to demonstrate altered binding properties or substrate range. This
could circumvent the likely resistance mechanisms and alter the spectrum of
activity.
It has been hypothesised that peptidoglycan hydrolases could have evolved
by the fusion of such modular domains (Garcia et al., 1988; Oshida et al.,
1995). This provides encouragement that designing chimeric antimicrobial
peptides could lead to highly active novel treatments for staphylococcal and
other infections being developed, and could even mirror events that have
occurred in vivo.
Previous studies have shown that peptidoglycan hydrolase fusions retain
their parental activities. A fusion of the Streptococcus agalactiae 830
bacteriophage endolysin to mature lysostaphin lyses both S. aureus and
Streptococcus agalactiae (Donovan et aI., 2006a). It is encouraging that
being part of a fusion protein does not inhibit the activity of either domain,
although this does not provide evidence that any additional activity is
conferred to the fusion. A second fusion of lysostaphin to a truncation of the
830 phage endolysin was also lytic to both S. aureus and S. agalactiae, and
it is suggested that the lysostaphin targeting domain could be contributing to
the activity of the phage endolysin, which had lost its weakly homologous
SH3b domain (Donovan et al., 2006a). However, it was also noted that the
truncated endolysin retained lytic activity against S. agalactiae on its own.
There have also been reports of multi-domain peptides developed with
highly specific bacteriolytic activity. Colicin la kills E. coli cells by forming a
channel in the cell membrane, causing lysis of the cell. Colicin la has been
fused to the AgrD1 pheromone of S. aureus, which is secreted through the
cell wall membrane initiating the cell signalling pathway, and is highly
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specific for S. aureus (Qiu et al., 2003). This multi-domain peptide,
pheromonicin-AgrD1 (PMC-AgrD1), has been shown to form channels in
lipid bi-Iayers. PMC-AgrD1 was shown to be bactericidal against S. aureus
including MRSA, but not against S. epidermidis or S. pneumoniae. Neither
of the domains alone had any inhibitory effect on growth of S. aureus,
demonstrating that the multi-domain peptide had a novel activity. PMC-
AgrD1 was also effective in a mouse model of MRSA sepsis and there was
no evidence of toxicity. A subsequent peptide was engineered using a
pheromone of E. faecalis fused to colicin la, which was effective in treating
mice in a model of VRE sepsis (Qiu et al., 2005). These results suggest that
multi-domain peptide fusions could provide effective antimicrobials with
novel activities and that this approach could lead to the development of
second generation Iysostaphins.
Several antimicrobial peptides, phage endolysins and staphylococcal
autolysins display a degree of homology to either the targeting domain or
endopeptidase domain of lysostaphin. Homologous peptides may be
particularly suitable for the inclusion in a chimeric second generation
lysostaphin, as the overall structure of the peptide may remain similar and
retain its function. By finding peptidoglycan hydrolases with homology to
lysostaphin, a group of candidate peptides can be identified for further study
in the development of such novel multi-domain antimicrobials.
1.8.2 Screening activity of novel antimicrobial peptides and second
generation Iysostaphins
During the development of novel antimicrobial peptides their bacteriolytic
activity must be assayed. There are a range of assay types available,
including agar plate and liquid assays, and assays against live cells, killed
cells and chemical substrates. These different assays have various
attributes, including ease of use, sensitivity and reproducibility, although
results between the different assays can often vary (Kusuma & Kokai-Kun,
2005). Enzymatic reactions to measure the hydrolysis of defined substrates
can be used to produce reliable quantitative results of peptidoglycan
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hydrolase activity (Kessler et aI., 2004). However, these reactions are not
representative of the effect of these enzymes in vivo. Whilst developing
novel antimicrobial peptides, including second generation Iysostaphins, it
would be invaluable to have access to a reliable, sensitive, quantitative
assay of activity against live S. aureus cells.
1.9 PROJECT AIMS
The general aim of this project is to develop novel antimicrobial peptides
with activity against MRSA. The approach described in this thesis is to
design chimeric, second generation lysostaphin enzybiotics. This was
through the testing of antimicrobial peptides domain functions, followed by
the alteration of the peptides, and the use of assays to determine any
improvement in activity and to screen for resistance. Changes in the activity
of peptides were then analysed.
Peptidoglycan hydrolases with homology to lysostaphin were identified as
candidate peptides. This thesis describes the cloning of candidate peptides
and the investigation of their bacteriolytic activity against S. aureus and
other bacteria. Other physical properties of the recombinant proteins are
also considered.
The design of a chimeric lysostaphin based antimicrobial peptide is
described, along with an analysis of its bacteriolytic properties, and a
comparison to the parental properties of the component domains.
In addition to the investigation and development of novel antimicrobial
peptides, the design of a novel assay for the screening of staphylolytic
activity of these peptides is described.
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2. MATERIALS AND METHODS
The general materials and methods that were used throughout chapters 3, 4
and 5, are described in this chapter. Further techniques used in the
development of the bioluminescence reporter assay are described in
chapter 5.
2.1 BACTERIAL STRAINS AND PLASMIDS
2.1.1 Media and growth conditions
Bacterial cultures were grown in LB or 2YT broth or on agar plates. Cultures
grown during cloning procedures used LB media and recombinant clones
were selected using medium supplemented with 100IJg ml' ampicillin.
Cultures grown for expression of recombinant proteins were grown in 2YT
media supplemented with 100IJg rnl' ampicillin. Unless otherwise described,
cultures were incubated at 37°C, and liquid cultures were subjected to
orbital shaking at 200rpm.
2.1.1.1 Luria-Bertani medium
One litre of Luria-Bertani broth was made by adding 10g bacto-tryptone
(Oxoid), 5g bacto-yeast extract (Oxoid) and 5g NaCI to 950ml of deionised
water. The pH was adjusted to 7.0 with 5M NaOH, and the volume was
made up to 1L using deionised water, prior to autoclaving at 121°C for 20
minutes.
To make LB agar, bacteriological agar (Oxoid) was added to the broth
recipe to a final concentration of 1.5% w/v.
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2.1.1.2 2YT medium
One litre of 2YT broth was made by adding 16g bacto-tryptone (Oxoid), 10g
bacto-yeast extract (Oxoid) and 5g NaCI to 950ml of deionised water. The
pH was adjusted to 7.0 with 5M NaOH, and the volume was made up to 1L
using deionised water, prior to autoclaving at 121 °C for 20 minutes.
To make 2YT agar, bacteriological agar (Oxoid) was added to the broth
recipe to a final concentration of 1.5% w/v.
2.1.2 Bacterial Strains
Bacterial strains used are listed in Table 2.1 and were stored in LB broth
with 100/0 (v/v) glycerol at -BOaC.
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Table 2.1 List of strains used through this project with relevant features and sources
Strain Relevant features / Reference / Source
genotypes
E. coli
DH5a LacZDM 15 recA1 Invitrogen
ER2566 LacZ::T7A (DE3) New England Biolabs
BL21 (DE3) araB::T7 Invitrogen
S. aureus
Mu50 Sequenced VISA (Kuroda et al., 2001)
RN450 Laboratory strain (Novick, 1991)
EMRSA16 Clinical isolate OMC, Nottingham
MRSA SCCmec types
lA, II, III and IV Clinical isolates OMC, Nottingham
RN6390 Laboratory strain (Novick, 1991)
NTC 6571 Oxford staph (Heatley, 1944)
Micrococcus luteus Environmental isolate University of Nottingham
S. epidermidis
S.pyogenes
'?- Clinical isolates OMC, Nottingham
S. haemolyticus
S. sciurii
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2.1.3 Plasmids
The full list of plasmids used in this study is presented in Table 2.2. pGEMT-
Easy (Promega) was used as an intermediate vector during cloning. pET21 a
and pET21 d (Studier & Moffatt, 1986) (Novagen) were used as expression
vectors for genes of interest. Plasmid maps are shown in Figure 2.1 and
Figure 2.2. The sequences of constructs generated as part of this project
are shown in the appendices. These highlight the restriction sites used to
make the clones and indicate the pET vector used. Expression is under the
control of T7 bacteriophage transcription and translation signals. Reverse
PCR primers were designed to remove the 3' stop codons and incorporate
the vector sequence encoding a C-terminal hexahistidine tag, enabling the
purification of recombinant protein by nickel-chelate chromatography
(Garinot-Schneider et aI., 1996).
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Table 2.2 List of plasmids used through this study
Plasmid Description / Protein encoded Reference
pGEMT-Easy Intermediate cloning vector Promega (Figure 2.1)
pET21a Expression vector (Studier et al., 1986);
Novagen; (Figure 2.2)
pET21d Expression vector (Studier et al., 1986);
Novagen; (Figure 2.2)
pKP1 Phage P68 Lys16 Appendix I
pUHHOLY1516 ORF15/16 from P68 genome (Takac et al., 2005b)
pKP2 Atl glucosaminidase Appendix II
pKP3 LssT: Atl GL chimera Appendix III
pKP4 Truncated Atl GL Appendix IV
pKP5 GFP tag in pGEMT Appendix V
pKP6 GFP tagged Atl GL Appendix VI
pKP7 GFP tagged GL' Appendix VII
pKPB R123GL Appendix VIII
pKP9 Atl amidase Appendix IX
pKP10 Atl R12 Appendix X
pKP11 Atl R3 Appendix XI
pEA3 Mature lysostaphin (Antoniadou, 2004)
pLss-T-GFP GFP tagged LssT Appendix XII
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Figure 2.1 Plasmid map of pGEMT-Easy (Promega)
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Figure 2.2 Plasmid map of pET21a (Novagen). pET21d is a 5440bp plasmid, based
on pET21 a with the removal of two base pairs following the BamHI restriction site at
position 198, and the replacement of the Ndel site with an Neol site at position 238
with the loss of one base pair.
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2.2 MANIPULATIONS OF DNA
2.2.1 Isolation of genomic DNA
Genomic DNA was extracted from overnight cultures grown in LB broth
using the Wizard Genomic DNA Purification kit (Promega) according to the
manufacturer's protocol.
2.2.2 Isolation of plasmid DNA
Plasmid DNA was extracted from 3ml of overnight cultures of E. coli DH5a,
grown in LB broth, using the Wizard Plus SV Miniprep kit (Promega)
following the supplier's instructions. Larger stocks of plasmid DNA were
isolated from 50ml of culture with the Qiagen Plasmid Midi kit, in accordance
with the manufacturer's protocol. The concentration of DNA was measured
using a NanoDrop ND1 000 spectrophotometer.
2.2.3 Restriction and ligation of plasmids
Endonuclease digestion of plasmid DNA was carried out according to the
methods of Sambrook et al. (Sambrook, Fritsch & Maniatis, 1989).
Restriction enzymes and appropriate buffers from New England Biolabs
were used. DNA fragments were ligated using the Rapid DNA Ligation kit
(Roche) as directed by the supplier's instructions.
2.2.4 Agarose gel electrophoresis
DNA was analysed by agarose gel electrophoresis as described by
Sambrook et al. (1989).
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2.2.5 Purification of DNA from agarose gels
DNA was extracted from agarose gels using the QIAEX " gel purification kit
(Qiagen) in accordance with the manufacturer's instructions.
2.2.6 Polymerase chain reaction
The polymerase chain reaction (PCR) (Saiki et al., 1985) was performed in
an Eppendorf Mastercycler Personal thermocycler. Pwo polymerase
(Roche) was used during cloning procedures. Taq polymerase (Roche) was
used for the PCR screening of recombinant clones. PCR reactions used to
amplify sequences for subsequent cloning procedures comprised 11J1 DNA
polymerase, 21J1 template DNA, 51J1 x10 Buffer +Mg2+ , 51J1 of each primer at
10mM, 51J1 dNTPs at 10mM and 271J1 ultrapure water (Sigma). Quantities
were halved for 251J1 volume screening reactions. The primers used through
this project are detailed in Table 2.3.
Standard PCR reactions consisted of; 95°C for 2 minutes, followed by thirty
cycles of 95°C for 30 seconds, 55°C for 40 seconds and 72°C for
40seconds. Finally, 72°C was held for seven minutes in order to ensure
complete elongation of all PCR products.
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Table 2.3 List of primers used in this project with their uses. Restriction sites are
underlined. Positions of primers used to amplify regions of the Atl gene are from
the published sequence of Oshida et a/., 1995, GenBank accession number
017366. Positions of primers for the cloning of P68 Lys16 are taken from GenBank
accession number AF513033.
Primer Sequence 5' - 3' Use
KP4 GCTCGAGTTTTACAGCTGTTTTTGGTTG Cloning. Reverse from
R2 of Atl: pas. 4300
KP9 CCCATGGCTTATACTGTTACTAAACC Cloning. Forward from
R3 of Atl: pas. 4301
KP10 CCTCGAGTTTATATTGTGGGATGTCGAAG Cloning. Reverse from
Atl GL: pas. 5743
KP11 GGCCATGGGTTGGAAAACAAAC Cloning. Forward from
lysostaphin targeting.
KP12 GTGCAGTCTGCAGCTTTATAGTTCCCCAAAGAAC Cloning. Reverse LssT
overlaps KP13.
Cloning. Forward GL'
KP13 CTATAAAGCTGCAGACTGCACCAACTGCTGTG overlaps KP12: pas.
4769
KP14 CCATGGCAACAACTACCCCTACTACACC Cloning. Forward fromR1 of Atl: pas. 3238
GCCATGGGTACTGCACCAACTGCTGTG Cloning. Forward fromKP15 Atl GL': pas. 4769
GCTCGAGGGAGCCCGGGTACCGGTAG Cloning. Forward fromKP16 GFP.
GCATATTTAGCTGTACCTGCTGC Sequencing of R123GL:KP17 pas. 4237
GTGTACCAGGTAAGTGGACAGATGC Sequencing of R123GL:KP18 pas. 5107
CCTCGAGAGCAGTTGGTGCAGTTAAATC Cloning. Reverse fromKP19 R3 of Atl: pas. 4884
GGCATATGGCTTCAGCACAACCAAG Cloning. Forward fromKP20 Atl amidase: pas. 2570
GCTCGAGTGAGAACACCCCCCAAGG Cloning. Reverse fromPTB10 P68 Lys16: pas. 11647
GGCCATGGCGAAATCACAACAACAAGC Cloning. Forward fromPTB12 P68 Lys16: pas. 12394
TGCTCGAGTTTGTAGAGCTCATCCATGCC Cloning. Reverse fromPTB20 GFP.
T7 TAATACGACTCACTATAGGG Sequencing from pET &pGEMT vectors.promoter
Sequencing from pETT7 CTAGTTATTGCTCAGCGGTGG vectors.terminator
SP6 Sequencing fromATTTAGGTGACACTATAG pGEMT vectors.promoter
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2.2.7 DNA sequencing
Samples of isolated plasmid DNA were sent to GeneService Ltd
(Cambridge) for sequence analysis.
2.2.8 DNA sequence analysis
Lasergene DNAStar software was used to analyse sequencing trace data.
DNA sequences in the published literature were found and compared using
the NCBI BLAST server (www.ncbLnlm.nih.gov).
2.3 TRANSFORMATION OF BACTERIA
2.3.1 Transformation of chemically competent E. coli DH5a
Aliquots of E. coli DH5a (Invitrogen) were made, and transformed as
described by the manufacturer's protocol.
2.3.2 Preparation of calcium chloride competent E. coli
A 50ml culture of E. coli cells was grown in LB broth to an 00 of 0.5 at
600nm and placed on ice for 10 minutes. Cells were collected by
centrifugation at 2700g for 10 minutes at 4°C and resuspended in 10ml of
ice cold 100mM CaCI2, 20% (v/v) glycerol. Cells were left on ice for 15
minutes before pelleting as above. Cells were resuspended in 2ml of
100mM CaCb, 20% (v/v) glycerol, left on ice for two hours, divided into
100 J..I I aliquots and stored at -BO°C.
2.3.3 Transformation of calcium chloride competent E. coli
Approximately SOng of DNA was added to 100 J..I I of cells and incubated on
ice for 30 minutes. The transformed cells were then heat shocked at 42°C
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for 45 seconds, placed on ice for two minutes, and then incubated for 40
minutes at 37°C after the addition of 4001J1 of LB broth. 1501J1 of cells were
then plated out onto selective plates.
2.4 CLONING PROCEDURES
2.4.1 Cloning into pGEMT-Easy
Purified PCR products were incubated at 72°C for one hour with 21J1 Taq
polymerase, 101J1 PCR buffer, 101J1 2mM dATP and made up to 1001J1 with
ultrapure water to introduce A' overhangs, based on the protocol given for
the pGEMT vector (Promega). These were then ligated into pGEMT
(Promega) as shown in Figure 2.1.according to the manufacturer's
directions. Recombinant clones were identified as white colonies when
grown on plates containing 40IJg rnl' X-Gal, due to the disruption of the ~ ~
galactosidase gene by insert DNA.
2.4.2 Cloning into pET21 vectors
Plasmid DNA isolated from pGEMT-Easy clones was digested with the
appropriate restriction enzymes. Purified DNA fragments were ligated into
pET21 vectors previously cut with the same restriction enzymes.
2.4.3 Screening of recombinant clones
A single colony of E. coli DH5a transformed with the relevant plasmid was
used to inoculate 5ml of LB broth supplemented with 100IJg rnl' ampicillin
and incubated at 37°C. Once the culture was turbid a 21J1 sample was used
as a template for PCR screening reactions as described in method 2.2.6.
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2.5 EXPRESSION AND ANALYSIS OF RECOMBINANT PROTEINS
2.5.1 Small scale protein expression screening
A single colony of E. coli BL21 transformed with the relevant plasmid was
used to inoculate 5ml of 2YT broth supplemented with ampicillin. At an
00600 nm of 0.5, IPTG was added to a final concentration of 1.5mM.
Following two hours incubation at 37°C with orbital shaking at 200rpm, the
culture was analysed by SOS-PAGE for the presence of the over-expressed
protein.
2.5.2 Large scale over-expression of recombinant proteins
500ml of 2YT broth was inoculated with a 5ml culture of E. coli BL21,
transformed with the relevant plasmid, grown to an 00600 nm of 0.25.
Cultures were incubated at 37°C with orbital shaking at 200rpm until an
00600 nm of 0.5 was reached after which they were moved from 37°C to
30°C. After 30 minutes incubation IPTG was added to a final concentration
of 1mM and the culture incubated at 30°C with shaking at 200rpm for two
hours. Cell pellets were harvested by centrifugation at 8000g for 10 minutes
at 4°C in a Beckman Avanti J201 centrifuge.
2.5.3 SOS - polyacrylamide gel electrophoresis (50S-PAGE)
80S-PAGE gels were run using an AUo mini-gel system. Gels were poured
with a 60/0 stacking layer and a 12% or 160/0 resolving gel, and run as
described by Sambrook et al., (1989). Protein samples were mixed with an
equal volume of 2x protein loading buffer (50mM Tris-HCI pH6.8, 100mM
dithiothreitol (OTT), 20/0 (w/v) lauryl sulphate, 0.1 % (w/v) bromophenol blue,
100/0 (v/v) glycerol) denatured at 100°C for one minute, cooled and loaded
into the gel. Protein molecular weight markers (New England Biolabs) were
loaded alongside samples. SOS-PAGE gels were stained with Coomassie
Blue stain (Coomassie Blue 1.25g/l, 500/0 (v/v) methanol, 100/0 (v/v) acetic
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acid in distilled H20) for one hour and de-stained, initially in rapid de-stain
(400/0 (v/v) methanol, 10% (v/v) acetic acid in distilled H20) for 30 minutes,
and then in slow de-stain (100/0 (v/v) methanol, 7.5-100/0 (v/v) acetic acid in
distilled H20) until the background stain was minimal, replacing the de-stain
as necessary.
2.5.4 Purification of recombinant proteins by nickel-chelate
chromatography
The purification of recombinant proteins by nickel-chelate chromatography
was carried out by an adaptation of the protocol of Bardelang (Bardelang,
2002). Cell pellets from 500ml cultures collected as described above were
gently resuspended in 30 ml cold Nic buffer (20mM imidazole pH 7.0, 50mM
NaCI, 100/0 (v/v) glycerol, 1mM PMSF). Cells were lysed by three passages
through a French Press (SIM-Aminco) on high ratio at 9000Psi, and the cell
lysate was spun twice at 25,000 g, at 4°C in a Sigma 3k30 centrifuge for 30
minutes to remove cell debris and precipitated protein. A 5 ml HiTRAP
affinity column (Amersham Biosciences) was used for nickel-chelate
chromatography. The column was charged with a 12ml injection of 50mM
NiS04 , and equilibrated in 15 ml buffer B (25mM NaH2P04 pH 7.0, 0.5 M
NaCI, 5°1<> (v/v) glycerol, 1 M imidazole) and 25 ml buffer A (25mM NaH2P04
pH 7.0, 0.5M NaCI, 50/0 (v/v) glycerol, 0.2mM imidazole). NaCI and Triton
X100 were added to the cleared lysate to final concentrations of 0.5 M and
0.1 % (v/v), respectively, and the solution applied to the column at a flow-rate
of 1 ml min'. Once loaded the column was washed with 20 ml of a 95%
buffer A: 5% buffer B mix to elute all unbound proteins from the column.
Bound protein was eluted from the column using a linear gradient of 5-850/0
buffer B in a total volume of 50 ml. The flow through was monitored using a
UV absorbance meter. 2ml fractions eluted from the column were collected
and stored on ice. Fractions eluted over the peak UV absorbance were
analysed by SDS-PAGE to confirm protein size, pooled, and then
transferred to BioDesign Dialysis Tubing (MWCO 8 kDa) and dialysed
54
overnight against 2L of buffer A supplemented with 0.05% (v/v) Triton X1 00.
Proteins were then aliquoted and stored at -80°C.
2.5.5 Purification of recombinant proteins by pH based denaturing
protocol
Cell pellets from 500ml cultures that were grown and induced to over-
express recombinant proteins, as described in method 2.5.2, were gently
resuspended in 10 ml Buffer B (8M urea, 0.1 M NaH2P04, 0.01 M Tris-HCI,
pH8.0) and incubated at room temperature for 30 minutes. Cell suspensions
were kept on ice and disrupted by sonication using a Sanyo MSE Soniprep-
150 at amplitude of 8 microns for 40 cycles of 20 seconds on and 30
seconds off. Where otherwise indicated, cells were lysed using the French
Press as described in section 2.5.4. Cell debris was removed by two forty
minute centrifugations at 25,000g, at 4°C using a Sigma 3k30 centrifuge. A
5ml HiTRAP affinity column (Amersham Biosciences) was charged with a 12
ml injection of 50mM NiS04, then equilibrated in 23ml Buffer C (8M urea,
0.1 M NaH2P04, 0.01 M Tris-HCI, pH6.3). The soluble protein in Buffer B was
loaded onto the column at a flow-rate of 1 ml rnin', and the column was
washed with 25mI of Buffer C. Protein was eluted with Buffer E (8M urea,
0.1 M NaH2P04, 0.01 M Tris-HCI, pH4.5) and 2ml fractions were collected
and stored on ice. The flow through was monitored using a UV absorbance
meter. Fractions eluted over the peak UV absorbance were analysed by
SDS-PAGE, and fractions containing the recombinant protein were pooled
and transferred to BioDesign Dialysis Tubing (MWCO 8 kDa).
Proteins were re-natured by sequential dialysis steps at 4°C;
(1) Against 2L of 100mM NaH2P04 (pH?), 1mM EDTA, 4M urea, 5%
sucrose, 100mM NaCI, 100mM KCI, 100mM L-arginine, 4mM MgCb, for 48
hours without stirring.
(2) Against 2L of the buffer in step 1 diluted 1:1 with 100mM NaH2P04 (pH?)
for 24 hours without stirring.
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(3) Against 2L of the buffer in step 1 diluted 1:1 with 100mM NaH2P04 (pH?)
for 12 hours without stirring.
(4) Against 2L of 100mM NaH 2P04 (pH?) for 4B hours with very slow
stirring.
Insoluble precipitated protein was removed by centrifugation. The resulting
soluble protein solution was aliquoted and stored at -BOaC.
2.5.6 Determination of protein concentrations
Absorbance of protein samples at a wavelength of 2BOnm was measured
using a NanoDrop ND1000 spectrophotometer. Protein concentrations were
then calculated using the Beer - Lambert law:
Abs280 = E X path length x concentration.
Equation 2.1 Beer - Lambert Law
Where path length =1:
E = [(number of tryptophan residues x 5690) + (number of tyrosine residues x 1280)
+ (number of cysteine residues x 120)] _
molecular mass of protein
Equation 2.2 Calculation of molar extinction coefficients (E)
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Molecular Number of Number of Number of Molar extinctionProtein coefficientMass (Da) tryptophans tyrosines cysteines (cm -1 I m m ml -tl
P68 Lys16 29651 10 23 5 2.93
Atl GL 54764 9 32 0 1.68
GL' 37538 6 24 0 1.73
LssT: GL 48145 10 29 0 1.95
GL: GFP 82635 10 42 2 1.34
GL': GFP 83590 7 34 2 1.00
R123GL 92700 15 51 0 1.62
Atl ami 64267 9 41 0 1.61
Atl R12 39150 6 19 0 1.49
Atl R3 18938 3 8 0 1.44
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2.6 ASSAYS OF ANTIMICROBIAL ACTIVITY
2.6.1 The stab test
Single colonies of E. coli ER2566 or BL21 carrying the relevant plasmid
were stab inoculated onto LB agar plates and incubated overnight at 37°C.
5ml LB broths were inoculated with the indicator organisms and incubated
overnight at 37°C. Following incubation, the agar plates with lids removed
were placed face down onto paper towel saturated with chloroform for 2
minutes within a fume hood. The plates were then placed face up under a
Bunsen flame for 10 minutes to allow the residual chloroform to evaporate.
5ml of 0.7% (w/v) agar at 50°C was inoculated with 501J1 of overnight culture
of the indicator organism, gently mixed and poured over the surface of the
agar plate whilst molten. The overlays were left to set before the plates were
incubated overnight at 37°C. Stab tests were carried out in triplicate and
negative controls were included by the inclusion of a stab of E. coli ER2566
or BL21 containing pET21a or pET21 d without any insert.
2.6.2 Agar diffusion assay
5ml of 0.7% agar at 50°C was inoculated with 501J1 of overnight culture of
indicator organism, gently mixed, poured onto an LB agar plate and left to
set. Antimicrobial proteins were diluted to a range of concentrations in buffer
(25mM NaH2P0 4 (pH7), O.5M NaCI, 5% (v/v) glycerol) and 51J1 of each
dilution was dropped onto the surface of the agar plates. Buffer alone was
also dropped onto plates as a negative control. Plates were left for 10
minutes, and then incubated at 37°C overnight.
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2.6.3 Turbidity assay
The turbidity assay was based on that described by Kessler et a/. (Kessler
et a/., 1993). Cultures of indicator organisms were grown in LB broth to an
OD600nm of 0.6. Cells were collected by centrifugation at 8000g, for 8
minutes at 5°C in a Sigma 3K30 centrifuge. Cell pellets were washed with
25ml of ice cold 10mM Tris-HCI (pH?) followed by two washes with 25ml
deionised water. The final cell pellet was resuspended in 5ml deionised
water, frozen at -80°C and Iyophilised overnight. Cells were resuspended in
0.5 ml of 25mM sodium phosphate (pH?) and 5 0 ~ ~ aliquots were stored at -
80°C.
Turbidity assay experiments were carried out in a Wallac Victor/ 1420 multi-
channel counter. The quantity of Iyophilised cell substrate, typically 5-1 O ~ I I
required to reach an OD6oonm of -0.4 in a total volume 2 0 0 ~ ~ was
determined, and this quantity was then aliquoted across the wells of a
standard 96 well plate. Antimicrobial peptides were diluted in buffer (25mM
NaH2P04 (pH?), 0.5M NaCI, 5% (v/v) glycerol) to the concentrations of
interest, allowing for the volume of cell substrate used. Buffer alone was
added as a negative control. Peptides were added to cell substrate across
all wells simultaneously using a multichannel pipette and immediately
placed in the victor" counter. The OD6oonm was measured at approximately
35 second intervals for 20-60 minutes, with shaking between each
measurement. Triplicate measurements were made in all assays of peptide
activity. All assays were performed twice, and plots shown are a
representative plot from one of the assay runs.
2.7 PROTEIN BINDING STUDIES
2.7.1 Protection turbidity assay
The protection turbidity assay was based on the turbidity assay described
above. It was used to investigate the binding activity of a protein when
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through its effect on the known lytic activity of a similar protein, when both
proteins were added to cell substrate together. To identify binding activity of
a protein, it would be added to a final concentration tenfold higher than the
chosen lytic protein, or the highest possible excess where this was lower.
These were added to Iyophilised cells and 00600nm was monitored as
described above.
2.7.2 Microscopic analysis of GFP tagged protein binding
Overnight cultures of the bacteria of interest were diluted in water to a
dilution providing an even distribution of separate cells when viewed under
the microscope. 10JJI of cell suspension was mixed with 10JJI of suitably
diluted GFP tagged protein on a standard glass slide and covered with a
cover slip. Cells were then viewed by light microscopy and under u.v. light at
a magnification of x100 using a labophot-2 (Nikon) microscope. Images
were taken of the same field of view under both conditions.
2.7.3 Larger scale analysis of GFP tagged protein binding
250JJI of the overnight culture of interest was mixed with 250JJI of GFP
tagged protein, and incubated for 5 minutes at 37°C with gentle shaking.
Cell pellets were collected by centrifugation at 13200rpm in a bench top
microfuge (Eppendorf Centrifuge 84150), washed with 250JJI water and
viewed over a u.v. transilluminator (UVP) for evidence of GFP bound to
cells.
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3. INVESTIGATING A PUTATIVE AMIDASE FROM THE
S. AUREUS BACTERIOPHAGE P68
3.1 INTRODUCTION
3.1.1 The P68 bacteriophage
The P68 bacteriophage is a lytic, double stranded DNA phage of S. aureus.
Its 18,227 base pair nucleotide sequence has been published, GenBank
accession number AF513033, and P68 has been classified as belonging to
the order Caudovirales, family Podoviridae, genus 'et>29-like phages' (Vybiral
et al., 2003). The genome of P68 contains 22 open reading frames, two of
which encode proteins with lytic activity against S. aureus. Protein 17 is a
virion associated murein hydrolase, thought to cause a localised rupture of
the cell wall to facilitate penetration of the phage DNA at the time of
infection. However, when subjected to the addition of purified protein 17, or
of a high multiplicity of infection with P68, S. aureus cells undergo
premature lysis (Takac & Blasi, 2005a). The second lytic protein, Lys16, is
responsible for host lysis following viral replication to release viral progeny,
and is believed to have D-alanyl-glycyl endopeptidase, and possible N-
acetylmuramoyl-L -alanine amidase activity. The initial description of Lys16
as a putative amidase from the genome sequence of P68 (Vybiral et al.,
2003) led to its identification as a potential anti-staphylococcal agent.
3.1.2 Structure of Lys16 of the P68 bacteriophage
The lys16 gene encodes a 250 amino acid protein, with a predicted
molecular mass of 28.5kDa and an isoelectric point of 8.6 (Vybiral et al.,
2003). The sequence of P68 lys16 displays similarity to the endolysins of
the S. aureus phages Twort and cp11 (Takac et al., 2005b). These
endolysins have a modular structure comprising an N-terminal D-alanyl-
glycyl endopeptidase, a central N-acetylmuramoyl-L-alanine amidase and a
C-terminal SH3b cell-wall targeting domain (Loessner et al., 1998; Navarre
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et al., 1999b). The N-terminal 112 amino acids of Lys16 show 43% and 57%
identity with the D-alanyl-glycyl endopeptidase domains of the <p11 and
Twort endolysins, respectively, whilst the C-terminus shows similarity to
each endolysin's cell-wall targeting domains. However, the central N-
acetylmuramoyl-L -alanine amidase domain is missing in P68 Lys16 (Takac
et al., 2005b). Double stranded DNA phages typically use a holin-endolysin
system to cause lysis of their host cell (Takac et al., 2005b). Holins insert
into the cytoplasmic membrane and cause localised disruption of the cell
wall, regulating access of the endolysins from the cytoplasm to the
peptidoglycan where they may cause cell lysis. Two predicted holin genes
have been identified within the sequence of P68. Hol12 is located
downstream of lys16, and encodes a class II holin, having two predicted
transmembrane domains (Takac et al., 2005b). A second holin gene, hol15
lies embedded in the -1 reading frame at the 3' end of lys16, and the
predicted protein has three transmembrane domains, characteristic of a
class I holin. Evidence suggests that hol15 has a dual start motif which can
lead to either the synthesis of an anti-holin or the lysis-effector (Takac et al.,
2005b).
3.1.3 Activity of Lys16 of the P68 bacteriophage
Muralytic activity of Lys16 has been demonstrated by zymogram against
autoclaved S. aureus 68 and E. coli TOP10 cells (Takac et al., 2005b).
Antimicrobial activity has also been shown by cell Iysates of E. coli
MC4100F' expressing the Lys16 protein against growing cultures of
S. aureus clinical isolates. Twelve out of fifteen isolates were lysed following
addition of Lys16 containing cell lysate, indicating that there is potentially a
wide host spectrum that Lys16 could be used against (Takac et al., 2005b).
Tests against identified S. aureus strains have not been reported. The
similarity of Lys16 to the endolysins of <p11 and Twort suggests its muralytic
activity against S. aureus is due to a D-alanyl-glycyl endopeptidase domain.
However, this does not explain the observed activity against E. coli, which
has different peptidoglycan cross-bridges to S. aureus and would not be
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susceptible. It may therefore be possible that N-acetylmuramoyl-L -alanine
amidase activity has been retained by Lys16 which could cleave the
peptidoglycan backbone at the MurNAc-L-alanine link (Takac et aI., 2005b).
3.1.4 Similar endolysins to Lys16 of the P68 bacteriophage
The activity of the endolysins of the Twort and cp11 bacteriophages has
previously been characterised. The endolysin of the Twort phage, belonging
to the Myoviridea family, has shown lytic activity against a S. aureus cell
substrate overlaid onto chloroform-lysed E. coli JM109 (DE3) carrying a
plasmid expressing the endolysin genes (Loessner et al., 1998). Truncated
enzyme fragments lacking the cell-wall targeting domain showed greater
activity than the full length endolysin. Partially purified protein was used to
demonstrate cleavage of staphylococcal cell wall substrate, and provided
evidence of N-acetylmuramoyl-L-alanine amidase activity (Loessner et al.,
1998). The cp11 bacteriophage belongs to the Siphoviridae family. Initial
studies assayed purified endolysin against cell wall substrate and
peptidoglycan to show that it is a bi-functional enzyme with endopeptidase
and amidase activity (Navarre et al., 1999b). More recently the recombinant
protein has been shown to lyse staphylococcal mastitis pathogens, including
S. aureus and coagulase-negative staphylococci (Donovan et aI., 2006b).
Activity of the cp11 endolysin has also been shown against heat killed
staphylococci and staphylococcal biofilms, with results indicating that the
intact SH3b cell-wall targeting domain is required for lysis of whole cells and
that maximum activity is seen when the endopeptidase and amidase
domains are combined (Sass et al., 2007).
The LysK endolysin of the staphylococcal bacteriophage K has also been
characterised. The phage has a wide host spectrum, and the activity has
been demonstrated by zymogram and agar diffusion assay against several
staphylococcal species including MRSA, VRSA, S. epidermidis, S. capitis,
S. caprae and Staphylococcus haemolyticus (O'Flaherty et aI., 2005). The
protein was obtained from Iysates of Lactococcus lactis expressing the
endolysin. It was not possible to purify the recombinant protein from E. coli
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as it was found to be located In the insoluble fraction of cell lysate as
inclusion bodies.
3.1.5 Aims of the chapter
This chapter describes efforts made to clone Lys16, express the
recombinant protein in an E. coli host and purify the protein. Assays using
cell Iysates and purified protein have been used to investigate the extra-
cellular activity of Lys16 against S. aureus, and a range of other
staphylococci and other Gram-positive species. The results of these assays
are used to determine the suitability of the candidate peptide Lys16 to be
used either as an antimicrobial, or to be incorporated into a chimeric
antimicrobial peptide with either the endopeptidase or cell-wall targeting
domain of lysostaphin.
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3.2 RESULTS
3.2.1 Validation of P68 Lys16 as a candidate peptide
The amino acid sequence of a putative amidase from the sequenced
genome of the P68 bacteriophage was BLAST searched to identify
homology to other peptides and conserved domains. This revealed an
N-terminal CHAP domain and a C-terminal domain showing homology to a
SH3b cell-wall targeting domain. The CHAP domain is a cysteine, histidine-
dependent amidohydrolase/peptidase, which is often found in proteins with
amidase activity, involved in peptidoglycan hydrolysis (Bateman & Rawlings,
2003; Rigden, Jedrzejas & Galperin, 2003). Other sequences were also
identified as showing similarity to the putative amidase from the P68
bacteriophage, including the endolysins of the cp11 and Twort
bacteriophages, and the SH3b cell-wall targeting domain of lysostaphin. The
homologous regions of Lys16 and lysostaphin show 390/0 identity, making
Lys16 a valid candidate peptide for incorporation into a chimeric peptide.
The alignment of the homologous regions of Lys16 and recombinant mature
lysostaphin is shown in Figure 3.1.
=--ys16
Lysostaphin
Lys16
Lysostaphin
Lys16
Lysostaphin
156
156
187
186
218
217
WKRNQYGTYYRNENGTFTCGFLPIFARVGSP
WK N+YGT Y++E+ +FT I R P
WKTNKYGTLYKSESASFTPN-TDIITRTTGP
PNGYTPYNEVCLSDGYVWGYWFQEPNKLSWG
Y+EV DG+VW + P SWG
AGQTIHYDEVMKQDGHVWSGVLKMPQFRSWG
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Figure 3.1 Alignment of homologous regions of Lys16 with lysostaphin
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3.2.3.2 Purification of Lys16 by nickel chelate chromatography
A SOOml culture of E. coli BL21 carrying pKP1 was grown and over-
expression of Lys16 was induced as described in chapter 2. Nickel chelate
chromatography was used to purify Lys16 from the cell pellet. However, a
large quantity of protein from the cell pellet precipitated out of solution
during cell disruption, and there was no evidence of Lys16 in the fractions
eluted by chromatography when analysed by SOS-PAGE (data not shown).
3.2.3.3 Purification of Lys16 by pH based denaturing protocol
A second cell pellet of E. coli BL21 (pKP1) induced with 1.SmM IPTG was
collected and the pH based denaturing protocol (see section 2.5.5) was
used to purify Lys16. SOS-PAGE analysis showed a protein of -2B.5kOa
was eluted from the column over several fractions (Figure 3.4), of which
fractions 7 to 13 were pooled together for the dialysis steps. Figure 3.4
shows the protein eluted in fraction 10. However, during dialysis a significant
quantity of Lys16 was observed to precipitate out of solution. Efforts to re-
solubilise Lys16 with the addition of glycerol to a final concentration of 5%
(w/v) did not succeed in reducing the quantity of precipitated protein. The
concentration of the remaining soluble Lys16 was determined as 22.BIJM,
which was stored at -BO°C.
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3.3 DISCUSSION
This study has described the cloning, and for the first time, purification of the
Lys16 endolysin of the P68 bacteriophage. A range of assays have been
used to test the activity of Lys16 against a range of Gram positive
organisms. The results of this study are compared and contrasted with
those of related studies.
3.3.1 Activity of P68 Lys16
Following its cloning and purification, Lys16 was assayed for activity against
a range of staphylococci and other Gram positive organisms by several
methods. No activity of the recombinant protein was observed by either the
turbidity assay or the agar diffusion assay when tested at a maximum
concentration of 2 2 . 8 ~ M M The stab test was also used to investigate the
activity of Lys16 released by lysed E. coli cells expressing the recombinant
protein. Again, no activity of Lys16 was observed. These results indicate
that either the recombinant protein is itself inactive, that Lys16 is not active
when used extracellularly, or that the recombinant protein is incorrectly
folded or rapidly degraded following purification.
3.3.2 Comparison to results of other studies of P68 Lys16
3.3.2.1 Zymogram assays
A separate study into the functional analysis of the lysis genes of the P68
phage has been carried out by Takac et al. (2005). The results of the study
were published after the work described in this chapter was carried out. The
aim of the work described in this chapter differed from the published study
by investigating the potential of the endolysin of P68 as an antimicrobial
agent. Takac et al. (2005) demonstrated muralytic activity of P68 Lys16
using zymogram assays. Zymogram assays use a heat killed cell substrate
incorporated into an SDS-PAGE gel. This is useful for determining the lytic
activity of a specific polypeptide band on an SDS-PAGE gel, but is
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inappropriate for investigating the antimicrobial potential of a peptide. The
study described in this chapter used assays against live cells, providing a
more representative model to investigate the antimicrobial activity of the
endolysin of the P68 bacteriophage. The muralytic activity seen by
zymogram analysis does provide evidence that the selection of Lys16 as a
candidate antimicrobial was justified.
3.3.2.2 eel/lysate assays
The other assay of lytic activity used by Takac et al. (2005b) involved IPTG
induction of a culture of E. coli MC41 OOF' with the plasmid carrying the lys16
gene, and sonication to produce a cell lysate which could be added to
growing cultures of S. aureus clinical isolates. Results of this assay are of
greater interest in assessing the potential antimicrobial activity of Lys16. In
its format this assay is closest to the stab test of the assays used in this
chapter, with the added effect of the addition of IPTG to induce over-
expression of the lys16 gene. The stab test described in this chapter relies
on the "leaky" expression of plasmid encoded genes that is seen when
using E. coli ER2566. The positive controls using pEA3 demonstrate that
the leaky expression of the lysostaphin gene is sufficient to cause cell lysis
in the overlay. Takac et al. (2005b) observed lysis in 12 out of 15 cultures of
clinical isolates from the Vienna General Hospital, whilst no lysis was
observed in the study described in this chapter using clinical staphylococcal
isolates from the Queen's Medical Centre, Nottingham, and against other
S. aureus strains and Gram positives. The geographical variation of
S. aureus strains between countries is well documented, especially amongst
MRSA, with the incidence of MRSA in Austria being approximately a third of
that of the UK, as recorded in 2001 (Enright et al., 2002; Stefani & Varaldo,
2003). This difference could indicate the variation between the
staphylococcal populations present in Vienna and Nottingham. Furthermore,
as only 12 of 15 clinical isolates from Vienna were lysed with the addition of
P68 Lys16 containing cell lysate, this provides further evidence that
susceptibility amongst S. aureus is incomplete. The clinical application of
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Lys16 alone would lead to the selection of resistant organisms, an event
that would progress more rapidly if the resistance determinant were
transferable.
3.3.2.3 Purified recombinant Lys16
The study published by Takac et al. (2005) did not use any assays of
purified protein. This chapter describes the purification of Lys16, the
problems encountered with using the purified protein, and the lack of an
observed activity of the purified recombinant Lys16.
3.3.3 Stability of P68 Lys16
Problems with the solubility of P68 Lys16 were experienced. Two different
techniques were used to purify Lys16, and minor modifications to each of
these were made in attempts to optimise the protocols. When using nickel-
chelate chromatography, maintaining the protein in solution prior to running
through the column was difficult, and no protein was found in the fractions
eluted from the column. These difficulties were solved using the pH based
denaturing method, as described in section 2.5.5, but Lys16 precipitated out
of solution whilst removing urea from its buffer by dialysis. Small quantities
of Lys16 were purified, but these rapidly deteriorated when removed from
storage at -80°C. This suggests that the inactivity of P68 Lys16 observed in
the agar diffusion assay and the turbidity assay may be due to the instability
of the recombinant protein. Either Lys16 has been incorrectly folded during
the purification process, or it is rapidly fragmenting or precipitating out of
solution over the course of the assay. Aliquots in which the protein was
observed to fragment may have become contaminated by a protease, and
were not used in assays of activity. However, protein was observed to
precipitate out of solution in all aliquots, demonstrating a separate,
independent instability of Lys16.
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LysK endolysin of the staphylococcal phage K was also found to be
insoluble when over-expressed in E. coli (O'Flaherty et al., 2005). The
recombinant protein was found to be located in inclusion bodies. This
demonstrates that the difficulties encountered with Lys16 are not unique,
and that solubility of the recombinant protein is a key issue in identifying
candidate endolysins.
3.3.3.1 The role of cysteine residues in Lys16
One explanation for the instability of the recombinant Lys16 is that the
protein has not been folded correctly. Cysteine residues often play a
structural role within proteins, with disulphide bridges forming between two
cysteines. The sequence of the recombinant Lys16 contains five cysteine
residues. One cysteine residue belongs to the conserved CHAP domain,
which confers amidase activity to P68 Lys16. The other cysteines may be
involved in the structure of the protein, and the conditions required for the
purification of Lys16, and when assaying its activity may be inappropriate for
the correct folding of the protein. Reviewing the literature relating to the
most similar phage endolysins to P68 Lys16, reveals that the sequence of
Lys16 shares three conserved cysteine residues with the Twort protein, and
only one with that of cp11. The study published on the Twort endolysin does
not include results showing activity of a purified protein against live cells
(Loessner et aI., 1998). However, recombinant cp11 endolysin has shown
lytic activity against live staphylococci (Donovan et al., 2006b; Sass et al.,
2007). The absence of the additional cysteine residues in the sequence of
the cp11 endolysin may enable its purification in an active form. It may be
possible to exploit the antimicrobial potential of Lys16 if a recombinant
protein lacking the additional cysteine residues could be designed and
purified without the loss of endolysin activity.
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3.3.4 The therapeutic potential of P68 Lys16
The results of this study do not support the selection of recombinant P68
Lys16 as an antimicrobial agent. The difficulties in purifying the protein and
maintaining it in solution are significant barriers to its practical application,
regardless of whether it has extracellular activity against S. aureus and
other Gram-positive organisms. The results of Takac et al. (2005b), in
showing activity against 12 out of 15 clinical isolates, demonstrate that even
if these purification problems are resolved, further work will be required to
determine the spectrum of susceptible S. aureus and understand the pattern
of resistance amongst other strains, prior to the promotion of P68 Lys16 as
a potential antimicrobial agent. Likewise, Lys16 is not a suitable candidate
peptide for the incorporation into a chimeric peptide alongside a domain
from lysostaphin.
3.3.4.1 A role for the P68 bacteriophage in phage therapy?
Although Lys16 has not been shown to be an appropriate antimicrobial, this
does not preclude the use of P68 in phage therapy. Use of the whole
bacteriophage would circumvent the problem of instability of the
recombinant protein. A study into synonymous codon usage of S. aureus
bacteriophages suggests that the lysis genes of P68 are likely to be
expressed rapidly by the host's translation machinery, and that P68 may be
useful in phage therapy (Sau et al., 2005). Incomplete susceptibility
amongst S. aureus strains would not prevent the use of P68 as part of a
"cocktail" of phages.
76
3.4 SUMMARY
The P68 bacteriophage is a lytic phage of S. aureus which causes lysis of
its host cell with the endolysin Lys16. This chapter has shown that P68
Lys16 is a poorly soluble and unstable protein. This is possibly due to
incorrect protein folding as a result of cysteine residues not interacting in the
necessary conformation during protein purification, and under assay
conditions. No lytic activity of Lys16 has been observed against
staphylococcal clinical isolates, laboratory S. aureus strains or other Gram-
positive organisms. These results show that Lys16 is not a suitable
candidate peptide to be used either as an antimicrobial peptide on its own,
or as part of a chimeric peptide with a domain from lysostaphin. If the
protein were to be purified and its solubility maintained, further work would
be required to determine the spectrum of activity against S. aureus strains,
and investigate potential resistance mechanisms. The P68 bacteriophage
itself may be useful as a phage therapy treatment, where a high level of
expression of Lys16 could lead to an effective treatment.
The principle of using a bacteriophage endolysin as an antimicrobial
remains attractive. This has been previously demonstrated by studies,
including in vivo models, of endolysins active against S. pneumoniae
(Loeffler et al., 2001; Loeffler et al., 2003b) and B. anthracis (Schuch et al.,
2002; Low et al., 2005; Yoong et al., 2006). As more phages of S. aureus
are isolated in the future, and their sequences determined, it may be
possible to predict the solubility and stability of their endolysins, enabling the
selection of active and stable candidate antimicrobials.
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4. ASSESSING THE POTENTIAL OF STAPHYLOCOCCAL
AUTOLYSINS AS ANTIMICROBIALS
4.1 INTRODUCTION
4.1.1 The autolysins of S. aureus
As previously discussed, bacteria use autolysins to cause localised cell wall
hydrolysis as part of the cell cycle. Other proteins identified as autolysins
also seem to playa role in pathogenicity and adhesion. S. aureus produces
several known autolysins including Atl, Aaa, LytM and SIe1 (Oshida et al.,
1995; Heilmann et al., 2005; Ramadurai et al., 1997; Kajimura et aI., 2005).
Autolysins are tightly regulated in vivo, as the uncontrolled expression of
these proteins could prove fatal to the cell. Producing a recombinant
autolysin which could be added at externally at high concentration provides
a potential source of novel antimicrobial agents.
4.1.2 Atl is the major autolysin of S. aureus
The predominant peptidoglycan hydrolase of S. aureus is Atl (Oshida et al.,
1995; Foster, 1995). The Atl autolysins have been shown to localize at the
septal ring, indicating its involvement in the cell division process (Yamada et
al., 1996). The characterisation of atl null mutants has shown inhibition of
cell-cell separation, causing cells to form large clusters, and sediment out if
grown in liquid media overnight without shaking (Sugai et al., 1995;
Takahashi et al., 2002; Biswas et al., 2006).
4.1.3 The structure of Atl
Atl is a bifunctional modular enzyme. The atl open reading frame is 3768bp,
encoding a 1256 amino acid protein of 137kDa (Oshida et al., 1995; Foster,
1995). The atl gene product is arranged with an N-terminal signal sequence,
78

to staphylococcal peptidoglycan the glucosaminidase could be an attractive
prospect as a candidate antimicrobial peptide. The modular structure of the
glucosaminidase presents the opportunity to substitute its targeting domain
with that of lysostaphin with the aim of designing a highly active, targeted
chimeric anti-staphylococcal agent.
4.1.5 The role of the repeat regions of Atl
The central region of At! contains three GW containing repeat regions,
approximately 150 amino acids in length. These repeat sequence regions
known as LysM (lysin motif) domains are widespread and have been shown
to bind peptidoglycan (Steen et al., 2003). Repeats one and two show the
greatest similarity with each other with an identity of 76%. Repeat three
shares 340/0 identity with repeat one, and 350/0 identity with repeat two
(Oshida et aI., 1995). Repeats one and two remain associated with the
mature amidase at its C-terminus, whilst repeat three is situated at the N-
terminus of the glucosaminidase. The difference in the sequence of repeat
three from the other repeat regions perhaps provides an explanation for the
difference in activity between the amidase and glucosaminidase seen in the
bacteriolytic assays. The repeat regions have been shown to be necessary
and sufficient for cell binding to S. aureus, and there are approximately 108
receptors on the cell surface, predominantly at the septal region (Baba et
al., 1998b). The precise nature of the cell surface receptor has not yet been
determined, although studies on the closely related AtlE of S. epidermidis
appear to rule out teichoic acid and the O-acetylation of peptidoglycan
(Biswas et al., 2006).
4.1.6 Effect of antibiotics on autolytic activity of Atl
Several studies have investigated the effect of antibiotics on the in vivo
autolytic activity of Atl. It has been shown that cell lysis following treatment
of S. aureus with penicillin G is due to the activity of Atl at the septal region,
where the synthesis of new peptidoglycan is inhibited (Sugai et al., 1997b).
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Autolysis also increases with exposure of the cells to oxacillin, whilst MRSA
strains show no increase in autolysis (Ledala, Wilkinson & Jayaswal, 2006).
This indicates a synergistic effect of Atl with cell wall synthesis inhibiting
antibiotics, which could be exploited by the use of the amidase or
glucosaminidase from Atl as antimicrobial agents.
Glycopeptide-intermediate S. aureus (GISA) show reduced expression of atl
and susceptibility to autolysis. This may contribute to the thickening of the
cell walls in these strains, with the thicker walls themselves contributing to
the resistance to autolysis (Koehl et al., 2004; Wootton et al., 2005). GISA
strains often show reduced susceptibility to lysostaphin (Boyle-Vavra et al.,
2001). A recombinant Atl hydrolase could be used to weaken staphylococcal
cell walls in tandem with lysostaphin.
S. aureus cells treated with the protein synthesis inhibiting antibiotics
tetracycline and chloramphenicol show decreased levels of autolysis
(Yamada et al., 2001; Ledala et al., 2006). Tetracycline has been shown to
inhibit the localisation of Atl, at high concentrations, to the septal region
(Yamada et aI., 2001). A recombinant Atl hydrolase lysostaphin's targeting
domain may show greater binding to the whole cell surface, and provide an
effective novel antimicrobial.
4.1.7 Aims of the chapter
This chapter describes the cloning of the recombinant Atl amidase and
glucosaminidase. The activities of these enzymes are investigated using a
range of assays. The potential of a chimeric peptide incorporating the
lysostaphin targeting domain is explored, and the results are compared with
those of the parent peptides. Results of assays of the chimeric peptide lead
to a further exploration of the role of the central repeat regions of Atl.
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bioluminescence, relative to the effect of a buffer control sample, is
recorded. Chapter five contains a further description of the bioluminescence
reporter assay, with the protocol described in section 5.3.1.7.
No activity of Atl GL was observed when assayed up to 10lJM In the
bioluminescence reporter assay (data not shown).
4.2.2 Design of a chimeric peptide; Atl GL with lysostaphin's targeting
domain (LssT:GL)
The results described above confirm the findings of studies previously
published. Recombinant Atl GL demonstrates lytic activity against M. luteus,
but no activity against S. aureus was observed. Following this it was
decided to design a chimeric peptide combining the active domain of Atl GL
with the lysostaphin targeting domain. This was aimed at addressing the
possibility that the lack of activity against S. aureus was due to the targeting
domain of Atl, with the aim of producing a chimeric peptide able to target
and lyse S. aureus.
4.2.2.1 Cloning of LssT:GL
Plasmid pEA3, carrying the gene encoding recombinant mature lysostaphin,
and genomic DNA isolated from S. aureus RN450 were used as templates
for a two stage PCR generating the IssT:GL chimeric DNA. Primers KP11
and KP12 were designed to amplify the C-terminal targeting domain of
lysostaphin with a 5' Ncol and a 3' Pstl restriction site. Primers KP13 and
KP10 were used to amplify the sequence encoding the C-terminal
glucosaminidase of GL without the R3 binding domain. This incorporated a
5' Pstl and a 3' Xhol restriction site, in frame with a C-terminal hexahistidine
tag sequence from pET21 (d). The two amplified sequences shared a 21 bp
overlap at the 3' end of the lysostaphin targeting domain sequence and the
5' end of the glucosaminidase. A second stage PCR was then carried out to
anneal the two sequences together using primers KP10 and KP11, as
shown in Figure 4.7. The chimeric sequence encodes a 429 amino acid
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4.2.4.1 Cloning of GFP tagged Atl GL and GL'
A GFP tag was designed with Xhol restriction sites at the 5' and 3' ends of
the sequence. Cutting out GFP with Xhol would leave a fragment which
could be ligated into a plasmid cut once with Xhol. When using pET21
vectors this would generate a sequence encoding the protein of interest with
a C-terminal GFP tag, provided that the peptide of interest's sequence does
not itself contain an Xhol site. The sequence of Atl GL does not contain an
Xhol site, allowing the GFP tagged proteins to be cloned in this way.
Primers KP16 and PTB20 (a gift from Philip Bardelang, University of
Nottingham) were used to amplify the GFP sequence from plasmid pLss-T-
GFP (also from Philip Bardelang), containing the GFP tagged lysostaphin
targeting domain, by PCR. This was ligated into pGEMT-Easy in E. coli
DH50, generating plasmid pKP5 and plasmid DNA was isolated. A sample
of plasmid DNA was sent for sequence analysis which confirmed the GFP
tag sequence was correct. The GFP tag was then excised and ligated into
plasmids pKP2 and pKP4 cut with Xhol. Ligated DNA was used to transform
E. coli BL21. Plates were screened to select colonies which carried plasmid
DNA in which the GFP tag had inserted in the correct orientation. As the
sequence has both 5' and 3' Xhol sites it may ligate into the singly cut
plasmid in either direction. Screening was performed by viewing plates over
u.v. light and selecting colonies which fluoresced green. Several green
colonies were observed (Figure 4.17), and these were picked and used in
stab tests against M. luteus to confirm that the tagged proteins retained lytic
activity. Both the GFP tagged Atl GL and GL' caused zones of clear lysis in
the bacterial lawn (Figure 4.18). The zones of lysis were observed to be
smaller than those caused by the untagged proteins, possibly due to the
larger GFP tagged peptides diffusing into a smaller area. Colonies of E. coli
BL21 that both fluoresced and demonstrated lytic activity were subcultured
and plasmid DNA was isolated. The organisation of the GFP tagged
glucosaminidases is shown in Figure 4.16. The plasmids encoding the GFP
tagged Atl GL and GL' were designated pKP6 and pKP7 respectively. E. coli
DH5a were transformed with plasmids pKP6 and pKP7, and a stock of
plasmid DNA was isolated from these.
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proteins. 5 ~ ~ of cells were mixed with 1 ~ I I 5 ~ ~ and 1O ~ ~ of the undiluted GFP
tagged glucosaminidases and viewed by phase contrast microscope. The
GFP tagged lysostaphin targeting domain was used as a control in assays
against S. aureus. No binding of the GFP tagged Atl GL or GL' was
observed to either M. luteus or S. aureus (data not shown). Aggregates of
fluorescence were visible under u.v. light. These did not resemble cell
clusters, more probably indicating small bodies of precipitated protein. GFP
tagged lysostaphin bound S. aureus cells as shown previously in Figure
4.10.
Larger scale binding experiments were also carried out as described in
chapter 2, combining equal volumes of cells and undiluted GFP tagged Atl
and GL' and viewing cell pellets. No evidence of protein binding to either
M. luteus or S. aureus was observed (data not shown).
4.2.5 Addition of R1 and R2 binding domains to Atl GL
In vivo the amidase and glucosaminidase of Atl separate between repeat
regions R2 and R3, leaving R3 with the glucosaminidase and R12 with the
amidase where they act as binding domains. A recombinant
glucosaminidase with the R1 and R2 binding domains at the N-terminus
may show improved binding properties, or a wider range of cell targets. The
extended Atl GL (R123GL) was cloned to investigate its activity and binding.
4.2.5.1 Cloning of r123g1
S. aureus RN450 genomic DNA was used as template DNA for the PCR
amplification of the At! glucosaminidase sequence with the additional R1
and R2 binding domains. Primers KP10 and KP14 were used to amplify the
r123g1 sequence with a 5' Ncol restriction site and a 3' Xhol restriction site
as shown in Figure 4.21. The 2537bp fragment was cloned via pGEMT-Easy
into pET21 (d)+ in E. coli DH50, as described in chapter 2, in frame with a
sequence encoding a C-terminal hexahistidine tag from the vector. The
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4.3 DISCUSSION
The glucosaminidase of Atl has been cloned and the recombinant protein
has been purified and tested for bacteriolytic activity. The results of these
assays are compared to the published literature. Following the work carried
out on the Atl GL a chimeric peptide was cloned combining the active
domain of Atl GL with the lysostaphin targeting domain. The antimicrobial
potential of this chimeric peptide was investigated and results are
discussed. Further to this, the binding of Atl to cell surfaces was investigated
in order to gain understanding of the results of the assays of activity. The
results of these studies are discussed in the context of the rest of the work
described in this chapter.
4.3.1 Bacteriolytic activity of the Atl glucosaminidase
The purified recombinant Atl glucosaminidase has been assayed for activity
against M. luteus and S. aureus in a range of assays, as well as the stab
test which utilises the leaky expression of proteins prior to purification.
Results from all of these assays are consistent with each other. Atl GL
demonstrates lytic activity against M. luteus. In the stab test Atl GL caused a
similar sized zone of lysis in the M. luteus overlay to that caused in lawns of
S. aureus by lysostaphin, a highly active anti-staphylococcal peptide. Using
the plate based agar diffusion assay, lysis of live cells can be observed at a
minimum concentration of 1 ~ M M In the turbidity assay, a liquid assay format,
the lytic effect of Atl GL against a M. luteus cell substrate can be detected
as low as 0.5 ~ M M These results demonstrate a high degree of activity of the
Atl GL against M. luteus.
No activity was detected in any of the assay formats against S. aureus.
Several isolates of S. aureus were used in each assay; Mu50, RN6390, and
clinical isolates including EMRSA16 and the Oxford staphylococcus. Other
staphylococcal isolates including S. epidermidis, S. haemolyticus, S. capitis
and S. sciutii were also used in the stab test, and no activity of Atl GL was
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recorded. The high level of activity seen against M. luteus is not observed
against S. aureus.
These results are consistent with the results of other studies published in
the literature. Oshida et al. (1995) demonstrated the activity of the
glucosaminidase of Atl against heat-inactivated M. luteus cells by zymogram
analysis, and also showed no activity against S. aureus. Activity of Atl GL
against heat-killed M. luteus and S. aureus cells has also been assayed in a
turbidity assay with results consistent with those reported in this assay
(Sugai et al., 1995). The agar diffusion assay and the stab test described in
this chapter represent the first report of the activity of Atl GL against live
cells, with the agar diffusion assay result being the first quantifiable assay of
the purified recombinant protein.
The bacteriolytic activity of Atl GL against M. luteus confirms that it is a
suitable candidate antimicrobial peptide for use against Gram positive
organisms. However, the lack of activity against S. aureus is an obstacle. If
the protein has no activity against staphylococcal peptidoglycan then it is of
little further interest. Atl GL has been shown to have e n d o - ~ - N N
acetylglucosaminidase activity and will cleave between sugar residues in the
peptidoglycan backbone at bonds present in staphylococcal peptidoglycan
(Oshida et al., 1995; Sugai et al., 1995). Therefore, if the Atl GL can be
correctly targeted to staphylococcal cell walls it may provide an effective
antimicrobial agent. Tests against purified staphylococcal peptidoglycan
could aid in the determination of this activity.
4.3.2 The chimeric peptide LssT:GL
The approach of fusing two hydrolytic proteins has previously been shown
to be successful using lysostaphin and an endolysin from the Streptococcus
agalactiae bacteriophage 830 (Donovan et al., 2006a). This demonstrates
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that separate hydrolases can maintain their activity within a chimeric
peptide. This approach was taken a step further by combining lysostaphin's
targeting domain with the Atl GL hydrolytic domain, with the aim of targeting
the glucosaminidase to staphylococcal cell walls.
In the stab test LssT:GL demonstrated a reduced degree of activity against
M. luteus and no bacteriolytic activity against S. aureus. Reduced hydrolysis
of M. luteus was anticipated, as the chimeric peptide was cloned without the
R3 binding domain from Atl GL. However the presence of the lysostaphin
targeting domain failed to confer activity against S. aureus. This could be for
one or more reasons. As discussed above it is unlikely, but possible, that
the Atl glucosaminidase does not have hydrolytic activity against
staphylococcal peptidoglycan, and that the presence of the glucosaminidase
in S. aureus is the result of an evolutionary event from which the amidase of
Atl was acquired. However, as discussed earlier the site of the proposed
activity of the glucosaminidase is present in S. aureus, and furthermore the
presence of anti-GL IgG inhibits the penicillin G induced lysis of cells (Sugai
et aI., 1997b). It may also be possible that the amidase and
glucosaminidase of Atl act synergistically in vivo, and that alone the activity
of Atl GL is insufficient to cause hydrolysis of the host peptidoglycan. This
may be part of a regulatory system which has evolved to prevent
uncontrolled autolysis of the cell. The study of Sugai et al. (1997) on the
inhibition of penicillin G induced lysis of S. aureus by anti-Ami and anti-GL
IgG indicates that the two peptidoglycan hydrolases act synergistically in
causing the lysis of cells weakened by penicillin G.
Another explanation for the inactivity of LssT:GL against M. luteus is that the
lysostaphin targeting domain within the chimeric peptide is incorrectly
folded, or that it binds to the staphylococcal cell wall in such a way as the
glucosaminidase does not have access to its site of action. If the lysostaphin
targeting domain was non-functional due to this, the bacteriolytic activity
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observed against M. luteus would not be due to the chimeric design of the
peptide. Subsequent results of binding studies using GFP-tagged
lysostaphin targeting domain demonstrated that the LssT is unable to bind
to M. luteus cells, and also that the truncated glucosaminidase alone,
lacking any recognised cell binding domain, is able to cause a similar
degree of bacteriolysis against M. luteus.
A positive outcome from this work is that the attachment of the lysostaphin
targeting domain to the N-terminus of the Atl GL does not prevent the
correct folding of the glucosaminidase into its active form. This indicates that
the future design of chimeric peptides combining a peptidoglycan hydrolase
with lysostaphin's targeting domain remains a viable strategy for the design
of novel antimicrobial peptides.
4.3.3 The truncated glucosaminidase
The truncated glucosaminidase, comprising only the C-terminal active
hydrolytic domain, was cloned to investigate whether the N-terminal R3
binding domain is essential for bacteriolytic activity against M. luteus. In the
stab test GL' was found to have a similar degree of activity against M. luteus
to the LssT:GL chimera. The purified protein was also shown to be active
against M. luteus in all of the assays tested, although less active than the
full size glucosaminidase. Using the agar diffusion assay the minimum
concentration of GL' which caused an inhibition in the growth of the bacterial
overlay was 25jJM.The turbidity assay required a concentration of 5jJM GL'
to cause a notable effect. These results show that without the R3 binding
domain the Atl GL is 5-10 fold less active against M.luteus. The residual
activity of GL' in the absence of a recognised cell binding domain may be
explained by the action of a highly active peptidoglycan hydrolase forming
interactions with the cell surface. A study on the AtlE autolysin of
S. epidermidis, which is closely related to Atl, has shown that the cell wall
lytic activity of the amidase domain is only slightly reduced with the removal
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of the R1 and R2 repeat regions, whilst the R1 and R2 domains exhibit a
good binding affinity to peptidoglycan (Biswas et al., 2006). This mirrors the
activity of the truncated glucosaminidase observed in the work described in
this chapter. This work also shows that this binding is able to cause cell
death in the absence of a separate binding domain.
GL' shows no bacteriolytic activity against S. aureus. This is consistent with
previous results, as the lack of a recognised cell binding domain could not
be expected to improve binding to staphylococcal cell surfaces.
The full size Atl GL and the truncated protein are both soluble proteins
which are stable when stored at -BO°C. The solubility and stability of these
proteins is an important feature in confirming the suitability of Atl GL as a
candidate peptide, as previously discussed in chapter 3. However, before
Atl GL could be further considered as a suitable candidate, greater
understanding of its cell binding is required, and this knowledge exploited to
better target the peptide to staphylococcal peptidoglycan.
4.3.4 Binding of Atl GL and GL' to cells
Atl GL and the truncated glucosaminidase were each tagged with GFP to
enable the visualisation of their binding to cells, and determine any
differences between the two proteins. Problems of protein solubility and
stability were experienced, but sufficient soluble, fluorescent protein was
purified to allow binding assays to be carried out. However, no fluorescent
protein was observed to bind to either M. luteus or S. aureus cells. Either
the GFP tagged protein was unable to bind to the cells or the number of
receptors on the cell surface is insufficient for enough protein to bind to the
cell to be visualised by phase contrast microscopy.
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Previous electron microscopy studies have shown that Atl binds at the site
of nascent septal rings, prior to cell division in vivo, and that the repeat
regions of Atl are responsible for targeting the peptidoglycan hydrolases to
this region (Yamada et al., 1996; Saba et al., 1998b). This may indicate that
the GFP tagged GL is binding to the site of cell division and that too little
protein is binding to the cell to be visualised in this way. The truncated
glucosaminidase, lacking the repeat region that is believed to target it to the
septal ring, may also have less specific, reduced binding which cannot be
visualised in this way.
The activity of the GFP tagged proteins against M. luteus in the stab test
demonstrate that the tagged proteins are able to bind to cell surfaces, and
that the GFP tag does not impede the attachment of the proteins to their
target site. However, the purified proteins were found to be poorly soluble.
The observation of fluorescent aggregates under the microscope suggests
that the tagged proteins were precipitating out of solution during the cell
binding assays. The precipitation of protein during the assay thus reduces
the amount of protein available to bind to cells, and this could also explain
the lack of binding observed. Alternative experiments were thus carried out
to gain an understanding of the binding of the Atl amidase.
4.3.5 The amidase of Atl
The amidase domain of Atl, complete with R1 and R2, was cloned and
tested for activity against M. luteus and S. aureus in the stab test. No activity
was observed against M. luteus. The amidase was active against S. aureus,
although the small zone of lysis indicates that the bacteriolytic activity is
significantly weaker than that of lysostaphin, and the level of activity
observed for the Atl GL against M. luteus. These results concur with studies
previously published in the literature (Oshida et al., 1995; Sugai et al.,
1995). Work on the amidase of the closely related autolysin AtlE from
S. epidermidis has also demonstrated activity of the purified recombinant
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protein against S. aureus peptidoglycan (Biswas et al., 2006). The
purification of the Atl amidase described in this chapter demonstrated that
the protein is poorly soluble, and as a result could only be tested at low
concentrations in the turbidity assay and the bioluminescence reporter
assay. The bioluminescence reporter assay showed that a 2.71JM
concentration of At! amidase caused a slight inhibition in the metabolism of
live, growing S. aureus RN6390 cells. However, in comparison with
lysostaphin, the inhibition of S. aureus was very weak. Lysostaphin at 0.51JM
caused a near complete abolition of bioluminescence.
The amidase of Atl was not investigated further as a candidate antimicrobial
peptide due its poor solubility, and its relatively low level of bacteriolytic
activity. Its ability to target S. aureus cells is of interest, and may be
exploited in the design of alternative antimicrobials.
4.3.6 The extended glucosaminidase R123GL
As the amidase of Atl has been shown to be active against S. aureus, the
R1 and R2 binding domains of Atl, which remain at the C-terminus of the
amidase in vivo, were cloned with the Atl GL to generate R123GL. The aim
was to investigate whether the addition of these binding domains would
enable the glucosaminidase to bind to S. aureus and cause cell lysis. The
R123GL was tested in the stab test against M. luteus and S. aureus. No
activity was observed against S. aureus, showing that the presence of the
additional binding domains is insufficient to confer activity of GL against
S. aureus. This suggests that the inactivity of Atl GL may not be due to poor
cell binding, but that the glucosaminidase alone is unable to cause lysis of
staphylococcal cell walls.
The R123GL showed reduced activity against M. luteus compared to the Atl
GL in the stab test. A possible explanation for this is that the large size of
the protein inhibits diffusion of the released protein through the overlay.
Alternatively, the reduced zone of lysis may be due to insolubility of the
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protein. Poor expression of the protein was observed in liquid cultures and it
was not possible to purify the recombinant protein. Without purified protein
the activity of R12GL could not be investigated further in the other assays.
Due to these problems R123GL was not considered further as a candidate
antimicrobial peptide.
4.3.7 The repeat regions of Atl
The repeat regions of Atl, shown to target the enzymes to the cell surface
(Saba et al., 1998b), were cloned as a method of investigating the binding of
the amidase and glucosaminidase. The R1 and R2 repeat regions were
cloned together to represent the binding domain of the Atl amidase to
S. aureus cells, and R3 was cloned alone as the binding domain of the
glucosaminidase to M. luteus cells. Initial tests of the purified proteins
confirmed that the repeat regions have no bacteriolytic activity. Protection
assays were then performed to investigate whether they would compete for
binding sites with the glucosaminidases and lysostaphin. Similar work on the
related autolysin Aas of Staphylococcus saprophyticus has shown that its
repeat regions are able to inhibit the lysis of a heat-killed cell substrate by
the amidase domain of Aas (Hell et aI., 2003).
The R12 binding domains demonstrated a protective effect for M.luteus
against lysis by Atl GL and GL'. This indicates that the R12 repeat regions
target the same cell surface receptor as the R3 repeat region and the
glucosaminidase. This may be anticipated from the high degree of similarity
between all three of the repeat regions. The inactivity of the
glucosaminidase alone against S. aureus is therefore unlikely to be due to
the inability of the R3 binding domain to bind to its cell surface. The lower
activity of Atl GL may be due to the O-acetylation of N-acetyl-muramic acid
residues which occurs in S. aureus but not M. luteus. This has been shown
previously for other hydrolases with glucosaminidase activity (Schleifer &
Steber, 1974). The results of this assay and those of previous studies
suggest that the role of Atl GL is in synergy with the amidase domain during
the regulated localised hydrolysis of peptidoglycan during cell division.
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Interestingly, the R3 repeat region did not have a protective effect from the
activity of the glucosaminidases on M. luteus. Conversely, it appeared to
restore lytic to the truncated glucosaminidase. This suggests that the R3
domain is able to form an interaction with GL' and increase the degree of
binding of the truncated glucosaminidase to the cell surface. Any interaction
of R3 with the full size Atl GL does not promote a higher degree of
bacteriolytic activity. Although R12 and R3 target the same cell surface
receptors as shown above, R3 appears to be able to form a positive
interaction with the glucosaminidase, whilst the R12 does not. This may
reflect the organisation of the Atl domains in vivo.
The results of the protection assays of R12 and R3 against the effect of
lysostaphin on S. aureus provide contradictory results. R3 provides no
protection to the S. aureus cells whereas R12 appeared to afford some
protection against the activity of lysostaphin. The lack of protection by R3
suggests that lysostaphin and the Atl hydrolases target different cell surface
receptors or have different recognition factors and bind to the same receptor
in a different way. As R12 and R3 are likely to share a common receptor,
the partial protection against lysostaphin by R12 seems unusual, and may
be explained by R12 and R3 also having different recognition factors.
Lysostaphin's and R12's recognition factors may be similar, and this could
explain the partial protection by R12 against lysostaphin. Alternatively, it
may be that the larger size of the two repeat regions of R12 plays a role in
this protection effect by steric hindrance.
As the above evidence indicates that lysostaphin and R3 have different cell
surface receptors or recognition factors, the design of the LssT:GL chimeric
peptide is likely to have altered the binding of the glucosaminidase to
staphylococcal cell surfaces. However, either the glucosaminidase was
unable to access its site of action, or the protein is not able to hydrolyse
staphylococcal peptidoglycan alone, as discussed earlier.
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4.4 SUMMARY AND FUTURE EXPERIMENTS
The activity and binding of the Atl amidase and glucosaminidase to
M. luteus and S. aureus has been investigated. The results of this study
show that the glucosaminidase has bacteriolytic activity against live
M. luteus cells, and the amidase has a lower degree of activity against
S. aureus. These results concur with the published literature and also
support the hypothesis that the GL acts in synergy with the amidase in vivo.
The R12 binding domain of the amidase and the glucosaminidase's R3
domain are targeted to the same receptor on the cell surface, and this is a
different receptor or has different recognition factors to that of lysostaphin.
Due to its low level of activity against S. aureus the Atl glucosaminidase is
not a suitable candidate as a novel antimicrobial peptide. The repeat regions
may be suitable binding domains to be incorporated into a chimeric peptide,
although further work is needed to investigate whether the localisation of the
peptide at the septal region might limit the lytic activity of the chimeric
peptide.
There are several further experiments that could be carried out to
investigate the activity and binding of Atl GL further. The nature of the
resistance of S. aureus to Atl GL could be examined to determine whether
an altered Atl GL may be an appropriate candidate peptide. This could be
through the cloning of S. aureus genomic DNA into M. luteus, and screening
the recombinant clones for resistance. Alternatively a S. aureus transposon
library could be screened for sensitivity to Atl GL. These methods could
enable the identification of genes responsible for resistance, and provide
useful information in the development of an altered GL.
Experiments could also be performed to create alternative chimeric peptides
incorporating the Atl glucosaminidase. Peptidoglycan recognition proteins
(PGRPs) are proteins produced by many organisms in the response to
bacterial infections. These may provide suitable alternative targeting
domains, and may broaden the spectrum of hydrolases such as Atl GL, if
combined in a chimeric peptide.
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Experiments may also be carried out to provide further understanding of the
nature of the binding of the Atl repeat regions. The combination of R12 with
the lysostaphin or LytM endopeptidase may reveal altered cell specificity,
and may also provide further evidence that by altering the targeting domain
of an antimicrobial peptide, the bacteriolytic activity can be changed. An
R12:LssE chimera could also be screened in the bioluminescence assay to
confirm whether R12 and the lysostaphin targeting domain have different
cell surface receptors.
In addition to the assays of antimicrobial activity used throughout this assay,
experiments should be performed using purified staphylococcal
peptidoglycan. This would help to determine the mechanisms of activity, and
the target sites of the Atl hydrolases, and such information would be
valuable in the exploitation of these proteins as potential novel
antimicrobials.
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5. Development of a bioluminescence reporter assay to
measure the effect of antimicrobial peptides on the
growth of S. aureus
5.1 INTRODUCTION
5.1.1 Assays of antimicrobial activity used in the literature
Several assays of activity of peptidoglycan hydrolases have been used
through chapters 3 and 4 of this thesis, and others have been used in other
studies published in the literature. These have been developed with various
aims including understanding mechanisms and sites of action as well as
assessing the use of potential antimicrobials. These assays each have
relative merits and disadvantages for the aims of this thesis in the
investigation of novel antimicrobial peptides as potential antimicrobial
agents. Some of these are discussed below, and the ideal assay format is
considered.
5.1.1.1 Zymogram assays
Many of the studies reported in the literature use zymogram analysis to
demonstrate the activity of peptidoglycan hydrolases. These included many
of the published studies of the Atl autolysin of S. aureus previously
discussed in chapter 4 (Oshida et aI., 1995; Sugai et al., 1995; Foster, 1995;
Biswas et aI., 2006). Briefly, the zymogram comprises running proteins of
interest down an SDS-PAGE gel containing heat killed cells as enzyme
substrates. Gels are then washed and incubated in phosphate buffer to re-
nature the electrophoresed proteins (Heilmann et al., 1997). Lysis of the
bacterial cell wall substrate leaves a clear area in the opaque gel, indicating
which protein bands have lytic activity against that substrate. This assay
format is very useful in the identification of hydrolytic proteins amongst
several proteins isolated from a bacterial culture of interest. It is also useful
as a relatively simple assay format that can assess activity from the lysate of
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cells over-expressing the protein without the need for purifying the
recombinant protein. However, the assay is not useful in the screening of
peptides as potential therapeutic antimicrobial agents. The assay utilises
heat-killed cells, thus not being representative of either their in vivo activity
or as a model of antimicrobial therapy. Furthermore, the assay is not
quantitative, and thus differences in the level of activity of peptides are
difficult to distinguish. Zymogram assays were not used in the course of this
project for these reasons.
5.1.1.2 Turbidity assays
Liquid turbidity assays have also been used in several of the studies
previously discussed, as well as a variant being used in this project. These
may use peptidoglycan preparations (Biswas et a/., 2006), heat killed cells
(Sugai et a/., 1995), or live cells (Donovan et a/., 2006b). The variation used
in this study uses a Iyophilised cell substrate and is described in chapter 2.
This is a versatile assay in which purified recombinant proteins or cell
Iysates can be tested. If purified protein is available the amount added can
be quantified, and the effect on turbidity can also be measured. The use of
live cells is commonly reported in the analysis of bacteriophage enzymes,
often showing the percentage survival of cultures after a set period of
incubation (Takac et aI., 2005a; Yoong et a/., 2006), although studies
showing the decline of turbidity against time have been published (Schuch
et a/., 2002; Pritchard et a/., 2004; Grundling et a/., 2006b). However, the
use of live cells in turbidity assays has been shown to produce variable
results between assays (Donovan et a/., 2006b; Kessler et a/., 2004;
Kusuma et a/., 2005). Live cells were not used in turbidity assays through
this project. In common with using peptidoglycan or heat killed cells, the use
of heat killed cells may not be representative of the therapeutic activity of a
protein.
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5.1.1.3 The stab test
The stab test was used in the work described in this thesis as a rapid initial
assay to detect antimicrobial activity of recombinant clones. The leaky
expression of plasmid encoded recombinant proteins by E. coli ER2566 is
utilised by chloroform lysing the cells, which releases these proteins onto
the surrounding agar, where their activity against overlaid cells can be
detected. This provides a tool for detecting whether a protein has
antimicrobial activity before the over-expression and purification of the
protein has been carried out. This is useful for the analysis of proteins that
are difficult to over-express or purify. This assay is also a test of activity
against live cells, demonstrating that the level of peptidoglycan hydrolysis is
sufficient to cause cell lysis and death. However, the stab test is only used
as an initial test as it is hard to quantitate and may not detect low levels of
peptidoglycan hydrolysis. Large proteins may also provide artificially
reduced zones of lysis, due to a lower rate of diffusion through the overlay
agar. Furthermore, proteins are also released from the E. coli host. Controls
show that E. coli ER2566 carrying a pET21 plasmid does not cause any cell
lysis alone in the stab test, but it is not possible to discount the possible
effect of any interaction between host proteins and the recombinant protein
of interest. This is a problem not only with the stab test but also with other
assays using unseparated proteins from cell lysate.
5.1.1.4 The agar diffusion assay
The agar diffusion assay is a plate based assay against live cells that has
been used in this project. Use of a similar assay has been reported in the
literature by Schuh et al. (2002). It can be used to rapidly screen for
bacteriolytic activity against a range of organisms. The assay is semi-
quantifiable, as a wide range of concentrations can be tested
simultaneously, providing an initial indication of the level of activity of a
protein. This information may then be used in choosing the concentration
range for a liquid assay format. The use of a liquid assay format is required
as the effects of proteins are poorly quantifiable, with little detectable
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difference In the zones of lysis at concentrations above the minimum
inhibitory concentration. A study comparing methods of assaying
lysostaphin reports that a similar disc-diffusion assay produces the most
reliable simple assay results, but that further measurements are required, as
increases in concentration fail to produce correlating increase in zones of
lysis due to poor diffusion of the protein (Kusuma et a/., 2005). Unlike the
stab test, which is a similar assay format, any bacteriolytic activity observed
may be attributed to the protein solution dropped onto the plate, providing
the correct controls have been performed.
5.1.1.5 Microscopic studies of activity
The visible effect on cells exposed to peptidoglycan hydrolases can be
performed using microscopic analysis. This has shown the dispersal of
cluster forming mutant cells by autolysins (Sugai et a/., 1995), and the effect
of producing null mutants of autolysins (Takahashi et a/., 2002; Biswas et
a/., 2006). These studies provide valuable information about the in vivo role
of proteins, particularly autolysins which do not cause host cell lysis.
However, they are neither rapid nor simple methods suitable for testing the
bacteriolytic activity of recombinant proteins against a range of bacterial
species.
5.1.1.6 In vivo assays
The use of animal models in in vivo assays of antimicrobial activity provides
the most representative assay format for the study of potential therapeutic
agents. These assays are suitable for well characterised, highly active
antimicrobial peptides such as lysostaphin and bacteriophage hydrolases
such as PlyG active against Bacillus anthracis (Patron et a/., 1999; Schuch
et al., 2002). However, the use of animal studies in the early stages of
investigating a thus far poorly characterised candidate antimicrobial peptide
is unjustified. Furthermore, such assays are unsuitable for measuring small
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differences whilst optimising the activity of recombinant antimicrobial
peptides.
5.1.1.7 Features of an ideal assay format
The ideal assay for measuring the activity of candidate antimicrobial
peptides will be quantifiable, reliable, simple, rapid and representative of the
activity of the protein against live cells. A liquid assay format is most easily
quantified as both the concentration of proteins can be controlled, and their
effect measured. Live cells provide a representative assay of activity, but as
has previously been discussed provide variable results in the turbidity
assay. Therefore, the ideal assay will be a liquid assay using live cells and
utilising a sensitive reliable reporter of the effect of added proteins on cells.
5.1.2 A bioluminescent growth reporter
A dual GFP - lux reporter under the control of a growth dependent promoter
has been developed in S. aureus (Qazi et al., 2001). The luxCDABE operon
of Photorhabdus luminescens is poorly expressed in S. aureus, and was
modified to introduce the lux sequences luxABCDE downstream of the gfp
gene under the control of the xylA promoter from Bacillus megaterium.
Bacterial luciferase uses reduced flavin mononucleotide as an energy
source and requires live cells for signal generation. The Lux proteins also
have a short half life, allowing emitted bioluminescence to be measured in
real time. The xylA promoter of the reporter is only expressed in actively
growing, log phase cultures, and bioluminescence readings fall after this
phase (Qazi et al., 2001). The PxyIA::gfp-luxABCDE reporter in S. aureus has
been used to visualise the invasion of cells by S. aureus and to monitor in
real time their intracellular replication (Qazi et al., 2001; Qazi et al., 2004).
This reporter presents an opportunity to develop a novel assay to measure
the antimicrobial activity of proteins. Novel peptides could be added to
growing cultures of S. aureus and the bioluminescence of the culture
measured as an indication of the effect of the added peptide on the
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metabolic state of the cells. This may provide a sensitive assay of
antimicrobial activity against live cells in a liquid format. Such an assay
would be a valuable tool in the development of novel antimicrobial peptides.
5.1.3 Aims of the chapter
This chapter describes the development of a novel assay to investigate the
antimicrobial activity of proteins against S. aureus. The assay is used to
screen several previously defined peptides and results compared with those
from other assays. Other novel peptides are assayed to determine whether
the assay is sensitive enough to detect small, previously unquantified
differences in activity. Future applications of the assay are considered.
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5.2 METHODS
Additional general methods to those described in chapter 2 are described
below. Specific methods used during the course of developing the assay are
discussed in the results section.
5.2.1 Bacterial strain and plasmid
S. aureus RN6390 was used in all assays (Novick, 1991).
Plasmid pSB2030 (PxyIA::gfp-/uxABCDE) was used in developing the assay
(Qazi et a/., 2001). The plasmid also confers resistance to chloramphenicol.
s. aureus RN6390 (pSB2030) was a gift from Saara Qazi, University of
Nottingham.
5.2.2 Growth media and conditions
s. aureus RN6390 carrying pSB2030 was grown in LB broth or on agar
plates supplemented with 5IJg rnl' chloramphenicol. Plates and liquid
cultures were incubated at 37°C, with broths being shaken at 200rpm. Cells
were stored in 100/0 glycerol at -BO°C.
5.2.3 Selection of bioluminescent cells
Fresh cultures were made from glycerol stocks for each experiment.
Colonies were screened for bioluminescence to ensure maintenance of the
reporter using a Hamamatsu VIM3 intensified video camera (Hamamatsu
Photonics).
5.2.4 Measurement of bioluminescence in assays
Cultures of S. aureus RN6390 (pSB2030) were grown, and bioluminescence
measured, in black sided 96-well plates in a Wallac Victor" multi-channel
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counter at 37°C. During the initial lag phase of culture growth
bioluminescence was measured at 8 minute intervals. 2 0 0 ~ ~ starting
volumes were used during assays of antimicrobial activity and
bioluminescence recordings were taken at intervals of approximately 35
seconds, with a shaking step between measurements. All measurements
were made in triplicate.
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5.3.1.2 Initial inoculum of cultures
As cultures are grown in 96-well plates it is not appropriate to inoculate the
broth in each well with a single colony as this would be both impractical and,
introduce variation between wells. LB broth was inoculated with 16 hour
overnight cultures of S. aureus (pSB2030) and grown in the Victor' multi-
channel counter at 37°C over a period of 7Y2 hours. A range of inoculum
sizes were used and bioluminescence was monitored to determine the
optimum conditions under which the log growth phase is reached as quickly
as possible, whilst ensuring a reliable emission of bioluminescence (Figure
5.2). As anticipated cultures receiving higher initial inocula emitted
bioluminescence earlier than cultures from a low inoculum. However, a
tenfold dilution causes a high initial spike of bioluminescence, followed by a
second peak of 630 CPS after approximately 90 minutes. A one in one
hundred dilution of the overnight culture reached mid-log phase after 4
hours reaching a slightly lower peak of 550CPS after 4 hours. Further
assays were performed using an initial dilution of overnight culture of one in
one hundred.
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and buffer that may be added to cells without causing a significant effect on
bioluminescence. As recombinant proteins to be tested may be at low
concentrations, this could represent a significant dilution of the culture. An
addition of 3 0 ~ ~ of buffer in a final volume of 2 0 0 ~ ~ was found to be the
optimum volume (data not shown), allowing a significant quantity of protein
to be added without a total loss of lux activity.
5.3.1.6 Temperature sensitivity of the assay
Initial experiments were carried out adding cold solutions of lysostaphin to
growing cultures. A rapid decline in the bioluminescence of the cultures was
observed (Figure 5.4). However, there was also a lag in the
bioluminescence of the buffer control cells. This background drop in
bioluminescence masks the full effect of the added protein. This is partially
due to the dilution effect seen in the addition of peptides discussed above.
However, the addition of cold peptides to the cells also slows down the
growth rate. By warming the proteins to 37°C prior to their addition, and
carrying out the addition of proteins in situ at 37°C the lag in buffer control
cells is reduced (Figure 5.5). Bioluminescence is shown as a percentage of
the initial bioluminescence to correct for slight variation between wells.
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5.3.1.7 Final format of the bioluminescence reporter assay
S. aureus RN6390 (pSB2030) were grown in a Wallac Victor2 multi-channel
counter in LB broth supplemented with 5 ~ ~ ml' chloramphenicol at 37°C to
mid-log phase, at a bioluminescence of 500CPS, after approximately four
hours. Proteins to be tested were warmed to 37°C and 3 0 ~ ~ added to empty
wells of the 96-well plate whilst still in the Victor' counter. 1 7 0 ~ ~ of cells was
added to each protein simultaneously using a multi-channel pipette. The
emitted bioluminescence was recorded immediately, as cells were incubated
at 37°C through the course of the assay. Further readings were taken at
approximately 35 second intervals with shaking between measurements.
Measurements of each assay were made in triplicate, and mean values
were plotted. All assays were performed twice, and plots shown are a
representative plot from one of the assay runs.
5.3.2 Validation of the bioluminescence reporter assay
5.3.2.1 Activity of lysostaphin in the assay
The activity of lysostaphin, a well characterised antimicrobial peptide was
investigated in the bioluminescence reporter assay. Lysostaphin was added
to final concentrations of 0.1 ~ M M 0 . 2 5 ~ M M O . 5 ~ ~ and 1 ~ M M All concentrations
of lysostaphin caused decrease in the bioluminescence of S. aureus
RN6390 (pSB2030) relative to the effect of buffer alone (Figure 5.6).
Concentrations equal and greater than O . 2 5 ~ ~ caused a rapid abolition of
bioluminescence. This indicates that the bioluminescence reporter is a
highly sensitive assay.
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peptides were all inactive when used alone in the turbidity assay, and all
provided protection to S. aureus against lysostaphin. Correlating with results
from a protection turbidity assay H83A was shown to provide partial
protection. Mutants H114A, H116A and H33A all provide a similar high level
of protection. The 037A mutant provided a particularly high level of
protection to S. aureus against lysostaphin, maintaining approximately
100% bioluminescence for 30 minutes. This distinction had not previously
been made using a turbidity protection assay.
5.3.3.2 Screening the Atl repeat regions against lysostaphin in a
protection assay
The binding domains of the Atl amidase and glucosaminidase, R12 and R3
respectively, were tested in a protection assay format against lysostaphin as
previously discussed in section 4.2.7.7. This demonstrated that the Atl
binding domains do not share a target receptor with lysostaphin.
5.3.3.3 Screening ofpeptides for antimicrobial activity
As discussed previously in chapter 4 the Atl amidase and glucosaminidase
were tested for activity in the bioluminescence reporter assay (sections
4.2.6.5 and 4.2.1.6 respectively). This showed that Atl amidase has weak
activity against S. aureus, and that Atl GL is inactive. Further to these the
bioluminescence reporter assay was used to measure the activity of other
candidate antimicrobial peptides. These included putative amidases
identified by sequence homology from S. aureus Mu50, and Staphylococcus
haemolyticus (from Philip Bardelang, University of Nottingham).
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5.4 DISCUSSION
5.4.1 Evaluation of the bioluminescence reporter assay
The bioluminescence reporter assay makes available an additional tool in
the investigation of the activity of novel antimicrobials. The assay has been
used to test lysostaphin, and several mutant Iysostaphins, previously
characterised using the turbidity assay format (Jarvis, 2005). Results of the
new assay correlate well with data from the turbidity assay, demonstrating
that the assay provides valid, reliable information. The assay also provided
a greater degree of discrimination between mutants in the protection assay
against lysostaphin. This indicates that the assay is highly sensitive, and
may be used to screen peptides for small differences in their activity.
By minimising the variation in the background bioluminescence of buffer
control cells it is possible to express the effect on bioluminescence in
relative light units. This ensures that results between assays are
comparable. This addresses one of the key aims in developing the assay.
The bioluminescence reporter assay is a liquid assay of activity against live
cells. Previously, as discussed earlier, use of live cells in the turbidity assay
has resulted in variation between assays (Kessler et al., 2004; Kusuma et
al., 2005; Donovan et al., 2006b).
The bioluminescence reporter assay should not be used as a sole screen of
activity of novel antimicrobials. Only live, actively growing S. aureus RN6390
(pSB2030) cells emit bioluminescence (Qazi et al., 2001). Any reduction of
bioluminescence is thus a measure of inhibition of cell growth. Further
assays, such as the turbidity assay, or the agar diffusion assay should be
used to investigate cell death and lysis. The bioluminescence reporter assay
should be used as an additional, highly sensitive assay to determine either
low levels of antimicrobial activity, or differences of activity between
antimicrobials with similar profiles as seen by other assay formats.
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5.4.2 Potential adaptations to the bioluminescence reporter assay
The bioluminescence reporter assay described in this chapter has been
developed as a measure of antimicrobial activity against the laboratory
strain S. aureus RN6390 containing the plasmid (pSB2030) of Qazi et al.
(2001). The assay could be used to investigate the activity of antimicrobials
against other S. aureus strains by transforming them with the reporter
plasmid pSB2030. The assay could also be adapted to measure the effect
on other organisms if a bioluminescent reporter plasmid suitably expressed
in that species is available or could be designed. Such alterations to the
assay would require that the assay conditions were optimised for that strain
or species, although the basic format may require little alteration.
The bioluminescence reporter assay has been developed as a liquid assay
format. There may be future interest in a variation of the assay based on
agar plates or other solid media. This could be used, for example, in a
model of biofilm formation. The bioluminescence reporter plasmid would be
suitable in screening antimicrobials designed to inhibit biofilm formation,
where there will be actively growing cells. The reporter would not be
appropriate in models of mature biofilms, as it is only expressed in actively
growing cells. In order for a solid assay format to be developed a reliable
method of measuring the bioluminescence would be required. This would
demand a highly sensitive camera system. It would also be necessary to
calibrate the assay against background bioluminescence from surrounding
regions on the media. The liquid assay format is carried out in black sided
96-well plates to prevent the transfer of bioluminescence between wells.
5.4.3 Future applications of the bioluminescence reporter assay
The bioluminescence reporter assay will be used in future screens of
antimicrobial activity using novel candidate peptides. It can be used as a
secondary screen to determine small differences in activity or detect low
levels of antimicrobial activity against S. aureus, as discussed above. It may
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also be used in further protection assays to investigate the binding
properties of novel antimicrobial peptides.
For example, as previously discussed in chapter 4, the bioluminescence
assay could be used to determine the binding profile and activity of a novel
R12:LssE chimeric peptide. This could confirm whether Atl and lysostaphin
have different cell surface receptors
An interesting potential role for the bioluminescence reporter assay is in the
development of mutant peptides. The assay has been shown to have the
ability to discriminate between the binding properties of mutant Iysostaphins.
Future candidate antimicrobial peptides, such as the amidase identified from
S. aureus Mu50 may be subjected to targeted mutagenesis with the aim of
increasing their binding or hydrolytic activity. The assay may be used to
identify those peptides with even slightly improved activity. Through further
sequential mutagenesis and screening steps a novel antimicrobial peptide
with superior activity to its parent peptide may be developed. This approach
may be used on a single domain from such a candidate peptide in the
development of a chimeric antimicrobial peptide. The bioluminescence
reporter assay could thus play a significant role in the development of a
novel, second generation, lysostaphin based antimicrobial peptide.
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5.5 SUMMARY
A bioluminescence reporter assay was developed to investigate the activity
of novel antimicrobial peptides against S. aureus RN6390 utilising the
reporter plasmid of Qazi et al. (2001). It is a liquid assay format against live
cells and results of different assays are reliable and comparable. Results of
the assay correlate with data previously obtained by the turbidity assay. The
bioluminescence reporter assay is sensitive and may be used in the
discrimination of peptides with similar levels of antimicrobial activity. The
assay adds another tool to those previously used to the investigation of
novel antimicrobial peptides active against MRSA.
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6. GENERAL DISCUSSION
6.1 INTRODUCTION
MRSA is an important nosocomial pathogen capable of causing a wide
range of infections. As multi-drug resistant MRSA strains develop resistance
to the drug of last resort, vancomycin and new antibiotics such as Linezolid ,
the threat of untreatable S. aureus emerging in hospitals and the community
increases. In order to meet this challenge there has been renewed interest
in alternative antimicrobial agents. One such agent is the antimicrobial
peptide lysostaphin. Lysostaphin is an endopeptidase produced by
S. simulans biovar staphylolyticus which cleaves the pentaglycine cross-
bridges of other staphylococci, disrupting the cell wall and subjecting the cell
to osmotic pressure leading to lysis and death. Lysostaphin has been
investigated in in vitro and in vivo studies and has successfully completed
phase 1/11 clinical trials. These results indicate that it is a promising
antimicrobial which could play a significant role in the treatment of
staphylococcal infections. However, the clinical introduction of lysostaphin
will lead to a selection pressure for resistance emerging. This demands that
measures are taken to address the future emergence of lysostaphin
resistant MRSA.
The work described In this thesis was aimed at developing second
generation novel Iysostaphins that have altered activity profiles and could
counteract any future resistance that may evolve. This work focussed on a
phage endolysin from the P68 bacteriophage of S. aureus, and the
glucosaminidase and amidase of the major autolysin of S. aureus; Atl. A
chimeric peptide combining the targeting domain of lysostaphin and the Atl
glucosaminidase was designed. The activity of this was investigated and
compared with the activity profiles of the parent peptides.
The activity of these proteins was investigated in a range of assays,
including a novel bioluminescence reporter assay that was developed during
the course of the work described in this thesis.
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6.2 THE LYS16 ENDOLYSIN OF THE P68 BACTERIOPHAGE
The genome sequence of the P68 S. aureus bacteriophage contains a gene
with homology to endolysins from the S. aureus phages Twort and <p11
(Vybiral et al., 2003; Takac et al., 2005b). As a peptidoglycan hydrolase with
in vivo activity against S. aureus P68 Lys16 was identified as a candidate
peptide for the development of second generation Iysostaphins.
6.2.1 Activity of Lys16
No bacteriolytic activity of recombinant Lys16 was observed against
S. aureus or M. luteus In any of the assays used. The maximum
concentration of Lys16 that could be used in the turbidity assay was
22.8IJM. Lysostaphin shows activity at concentration lower than 1IJM,
indicating that the Lys16 purified was not a promising candidate peptide.
The results described in chapter three contrasts with those of other studies,
reported after this work was completed. Lys16 was shown to have
extracellular bacteriolytic activity against S. aureus by zymogram assay, and
in a turbidity assay using E. coli cell lysate overexpressing the protein ( et
al., 2005b). However, as the focus of this thesis is to exploit peptidoglycan
hydrolases as potential enzybiotics it is important that active purified
recombinant proteins can be obtained.
6.2.2 Stability of Lys16
The recombinant Lys16 was found to be poorly soluble and unstable. It is
possible that this led to the apparent inactivity of the protein, due to its
precipitation during assays. Similar problems of solubility have been
reported for other staphylococcal phage endolysins (O'Flaherty et a/., 2005).
This is a significant obstacle when considering Lys16 as a candidate
antimicrobial peptide and further work concentrated on other candidates
with greater solubility and stability.
150
6.3 THE STAPHYLOCOCCAL AUTOLYSIN ATl
Autolysins are peptidoglycan hydrolases produced by bacteria to cause
highly regulated localised cell wall disruption during cell cycle processes. Atl
is considered to be the major autolysin of S. aureus and has been the
subject of much research interest (Oshida et aI., 1995; Foster, 1995;
Yamada et al., 1996; Saba et al., 1998b). Atl has been shown to be involved
in the cell separation process, and autolysins have been demonstrated to
have multiple cellular roles. None of the previously reported research has
considered the potential of Atl as a novel antimicrobial, and this was the
subject of the work described in chapter four.
6.3.1 Activity of the Atl peptidoglycan hydrolases
The glucosaminidase and amidase domains of Atl were cloned separately,
each with the repeat regions with which they are associated in vivo. Purified
recombinant protein was obtained and tested in a range of assays against
S. aureus and M. luteus. Results of these assays confirmed that the
glucosaminidase had lytic activity against M. luteus, whilst the amidase had
weaker activity against S. aureus, which had previously been reported by
other researchers (Oshida et al., 1995; Sugai et al., 1995). The work
described in chapter four extends this information and shows that the
purified recombinant protein is active against live cells, essential if the
autolysin is to be considered as a novel antimicrobial.
6.3.2 Binding of the Atl repeat regions
This study has also confirmed the role of the repeat regions in binding to the
staphylococcal cell surface, previously described by Saba & Schneewind
(1998). The repeats attached to each hydrolytic domain have been shown to
target the same cell surface receptor, and this has been shown to differ from
the surface receptor of lysostaphin or to have different recognition factors.
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This led to the development of a chimeric peptide containing the lysostaphin
targeting domain and the glucosaminidase domain of Atl.
6.4 THE DESIGN OF A CHIMERIC ANTIMICROBIAL PEPTIDE
The Atl glucosaminidase was cloned in a fusion with the lysostaphin
targeting domain, with the aim of conferring greater activity against
S. aureus. The LssT:GL chimera retained activity against M. luteus, but no
activity against S. aureus was observed. It was shown that the activity
against M. luteus was due to residual binding ability of the truncated
glucosaminidase, rather than the binding ability of the lysostaphin targeting
domain. Although this was a disappointment in the process of developing a
novel antimicrobial peptide active against MRSA it provides encouragement
to the strategy of developing multi-domain novel antimicrobials. The result
demonstrates that the domains within the chimeric peptide retain parental
properties, as has been shown by other researchers (Donovan et al., 2006a;
Qiu et al., 2003). Therefore if compatible catalytic and cell wall binding
domains can be identified, they may be fused to result in a chimeric novel
antimicrobial peptide with activity against MRSA, and therefore this is a valid
strategy to continue in the future.
6.5 A BIOLUMINESCENCE REPORTER ASSAY
A number of assays of bacteriolytic activity have previously been used to
study peptidoglycan hydrolases (Kusuma et al., 2005). These assays have
varied benefits and there is no single ideal assay with which to test a
potential novel antimicrobial peptide. The development of a bioluminescent
S. aureus growth reporter plasmid presented the opportunity to develop a
novel assay measuring the viability of live S. aureus cells (Qazi et al., 2001).
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6.5.1 Development of the assay
Using the S. aureus bioluminescence reporter of Qazi et al. (2001) a liquid
assay format was developed to measure in real time the effect of
recombinant antimicrobial peptides on cellular metabolism. The assay was
able to distinguish between novel chimeric peptides that had apparently
similar levels of activity when assayed by other tests. This highly
discriminatory assay could be a valuable tool in the future development of
novel antimicrobials. Minor modifications could be made to existing
candidate peptides and the bioluminescence reporter assay could be used
to screen for differences in antimicrobial activity.
The assay does require purified recombinant protein to be available and
should not be used in isolation. Other assays, such as the stab test, should
be used alongside the bioluminescence reporter assay, for initial
experiments to identify bacteriolytic activity. Furthermore, as
bioluminescence is a reporter of cell growth additional assays will be
required to determine whether cells are being killed and lysed.
6.6 EVALUATION OF ALTERNATIVE ANTIMICROBIAL AGENTS
The continuing emergence of antibiotic resistance in S. aureus requires
novel antimicrobial agents to be developed. These will include traditional
antibiotics and also alternative antimicrobial agents. No outstanding
candidate antimicrobials were identified through the work described in this
thesis. However, there are a number of other candidates available, and
hopefully these will provide our continuing protection against S. aureus
infections.
The ideal method of reducing the clinical impact of staphylococcal infections
would be to prevent infections developing in the first instance. With a view to
this there is significant interest in developing a S. aureus vaccine (Kuklin et
al., 2006; Stranger-Jones et al., 2006). These have shown some promise in
animal studies. The high mutability of S. aureus poses the threat that a
vaccine may become ineffective shortly after its introduction. Counteracting
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this threat will be a major challenge in the development of a successful
vaccine. If an effective vaccine is developed, protection programmes will be
costly to developing nations, and S. aureus will never be eradicated as there
is an animal reservoir as well as human carriers. There will therefore always
be a requirement for antimicrobials active against S. aureus. In any event,
until an effective vaccine is introduced it is of the highest importance to
pursue multiple lines of defence against S. aureus infections, and other
alternative treatments should be investigated.
Lysostaphin is a promising novel antimicrobial peptide active against MRSA.
Results of in vitro and in vivo studies and phase 1/11 clinical trials indicate
that it is an effective anti-staphylococcal agent and will be of particular
interest as a topical intranasal treatment to eradicate nasal carriage pre-
surgery, and as a coating for catheters and other indwelling medical devices
(Anon, 2003; Wu et al., 2003). Resistance to lysostaphin is likely to emerge
by one of several mechanisms and this should be considered with its future
clinical introduction.
There are further concerns over the application of lysostaphin as a
treatment for a wider range of infections. If lysostaphin is to have a role in
treating S. aureus infections such as pneumonia and endocarditis then its
safety as an intravenous treatment needs to be assessed. Previous studies
have not demonstrated any significant toxicity of lysostaphin and have only
detected modest inhibition of its anti-staphylococcal activity by antibodies
(Dajcs et al., 2002). Long term studies of the toxicity and immunological
response to lysostaphin are required, as patients may receive prolonged
treatment regimes, and may require treatment over several episodes during
their life. Concerns over the immunological effect of a bacterial protein
treatment led to the initial decline in interest in lysostaphin following
promising experimental results in the 1960s and 1970s. It may be possible
to overcome any potential immunological problems by engineering a
"humanised" second generation lysostaphin. If the sequence of lysostaphin
could be altered to resemble more closely that of a human protein, whilst
retaining its activity against S. aureus, it should provoke a lesser immune
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response, which would Improve and prolong the efficacy of such a
treatment.
If these concerns over future resistance and immunological response to
lysostaphin can be addressed, then lysostaphin remains a highly attractive
alternative antimicrobial. Research into the development of enzybiotics
based on lysostaphin, including multi-domain chimeric peptides should
continue. There are several candidates which may become components of
such a multi-domain peptide, or could be used as novel antimicrobials in
their own right.
Staphylococcal autolysins have been considered as potential candidates as
they have evolved to be highly specific peptidoglycan hydrolases. Exposure
to excessive concentrations of autolysins may cause rapid lysis, and thus be
an effective anti-staphylococcal treatment. However, autolysins have not
evolved to cause host cell lysis and play wide and varied roles in cellular
processes, the regulation of which is not fully understood (Smith et al.,
2000). The clinical implication of using a staphylococcal autolysin with
multiple functions may be complicated, and this could compromise the
efficacy and safety of such an antimicrobial. Furthermore, many of the
staphylococcal autolysins investigated are poorly soluble and unstable
proteins. For an antimicrobial peptide to have potential as a therapeutic
agent it needs to be a stable protein with extracellular activity. Taking into
consideration these drawbacks, there are stronger candidate peptides than
staphylococcal autolysins.
Bacteriophage endolysins have been the subject of recent research interest.
Encouraging results have been reported, demonstrating effective
antimicrobial activity in vitro and in vivo. Phage endolysins active against
B. anthracis and S. pneumoniae have been developed (Schuch et al., 2002;
Loeffler, Djurkovic & Fischetti, 2003a). These could provide highly specific
antimicrobial agents for treating specific infections. Narrow spectrum agents
may play an important role in the treatment of defined infections as they will
cause a reduced disruption to a patient's natural microflora. Broadly active
phage endolysins have also been identified, and these may playa role in
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the treatment of other undefined infections (Yoong et al., 2004). Many
bacteriophages of most bacterial species exist in nature, and their
endolysins provide an extensive pool of potential novel antimicrobials. To
exploit this, phages with the host range of interest, including S. aureus, need
to be isolated and identified. It is then key to identify which endolysins are
stable proteins with extracellular activity. An additional benefit of phage
endolysins is that the phages themselves could be used to develop second
generation endolysins in the event of resistance emerging. Phage
endolysins therefore present a strong case for further investigation as
alternative antimicrobials active against MRSA.
Other candidates include bacteriophage therapy itself, although concerns
may persist regarding the pharmacokinetics and immune response to such
a treatment. Other animal, plant or bacterial antimicrobial peptides may also
be identified with activity against S. aureus and could provide novel
alternative agents. Novel synthetic antimicrobial peptides with activity
against S. aureus have been designed, based on the active sites of insect
defensins (Saido-Sakanaka et al., 2005). As our knowledge and
understanding of lysostaphin, phage endolysins and other antimicrobial
peptides increases, it may be possible to develop more novel antimicrobial
agents in this way.
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6.7 FUTURE DIRECTIONS
Further work is required to identify and develop novel antimicrobial peptides
with activity against S. aureus, including MRSA. The most promising source
of candidate peptides could prove to be bacteriophage endolysins. Once
further bacteriophages of S. aureus have been identified and isolated it will
be possible to clone and purify recombinant endolysins. These may be
screened for activity in a range of assays, including the bioluminescence
reporter activity for activity against S. aureus and other organisms.
Endolysins that show promising activity may be developed as novel
antimicrobials or combined in a multi-domain chimeric peptide. If lysostaphin
shows continuing success as it progresses through the clinical trial phases
then second generation lysostaphin/phage endolysin chimeric peptide could
be of great therapeutic value. The lysostaphin endopeptidase could be
specifically targeted to staphylococci with a phage endolysin targeting
domain, or vice versa. Such combinations could improve and prolong the
efficacy of novel antimicrobial peptides active against MRSA.
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Appendix XIII.
The effect of plotting data from the bioluminescence
assay as a percentage of the negative control.
reporter
As described in chapter five, efforts were made to determine the optimum
conditions, and minimise the variability, of the bioluminescence reporter
assay. However, during assay runs cells continued to be metabolically active
and bioluminescence measurements of buffer control cells were not static.
There also remained some inherent variability in the assay format, due to the
effect on the host cell metabolism of many factors, including minor changes
in temperature, inoculum size, and the exact point in the growth curve at
which peptides were added. This variability during and between assays
caused difficulties in detecting low levels of activity, and comparing the
effects of test proteins in different assay runs.
In order to mitigate this variability, and enable the effective comparison of
results from different assay runs, data was plotted as; bioluminescence as a
percentage of the negative control. In each assay run the effect on
bioluminescence of buffer alone was measured alongside the effects of test
proteins. Traces were plotted from the starting bioluminescence, and for
each timepoint, the level of bioluminescence of cells to which a test protein
had been added was calculated as a percentage of the bioluminescence of
buffer control cells. Therefore, the bioluminescence reporter assay plots
presented in this study do not show traces of buffer control cells.
To illustrate the effect of presenting data in this format, Figure XII1.1 shows
the effect of the lysostaphin targeting domain; Mu50 amidase chimera at
1 . 8 ~ M M on bioluminescence of S. aureus RN6390 (pSB2030). Figure XII1.2
shows the same data presented as a percentage of the negative control.
Through plotting the data as a percentage of the negative control it can be
shown that the decrease in bioluminescence due to the effect of the chimeric
protein is separate from the initial background decrease seen in the buffer
control cells. Furthermore, this decrease is maintained as the
bioluminescence of the buffer control cells subsequently rises.
xx
Through removing the necessity to plot the buffer control, it is also possible
to expand the y axis over the range required for the effect of the test
proteins. This is useful as, if plotting bioluminescence itself, often the
decrease in CPS is relatively small compared to the background increase
seen in buffer control cells. This hampers the differentiation between similar
levels of activity if the buffer control trace is plotted. Therefore, by plotting
bioluminescence as a percentage of the negative control, variance between
assays can be reduced, and small changes in activity can be measured.
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